Document and Entity Information - USD ($)	12 Months Ended
Document and Entity Information - USD ($)	Dec. 31, 2015	Mar. 11, 2016	Jun. 30, 2015
Document And Entity Information
Entity Registrant Name	STRATA Skin Sciences, Inc.
Entity Central Index Key	0001051514
Current Fiscal Year End Date	--12-31
Entity Well-known Seasoned Issuer	No
Entity Voluntary Filers	No
Entity Current Reporting Status	Yes
Entity Filer Category	Smaller Reporting Company
Entity Public Float			$ 8,486,911
Entity Common Stock, Shares Outstanding		10,503,393
Document Fiscal Year Focus	2015
Document Fiscal Period Focus	FY
Document Type	10-K
Amendment Flag	false
Document Period End Date	Dec. 31, 2015

CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands	Dec. 31, 2015	Dec. 31, 2014
Current Assets:
Cash and cash equivalents	$ 3,303	$ 11,434
Restricted cash	15	0
Accounts receivable	4,068	220
Inventories	4,128	5,275
Prepaid expenses and other current assets	465	274
Total current assets	11,979	17,203
Property and equipment, net	13,851	1,961
Patents and licensed technologies, net	7,247	37
Other intangible assets, net	7,980	0
Goodwill	8,928	0
Deferred financing costs	1,293	821
Other assets	94	48
Total assets	51,372	20,070
Current Liabilities:
Note payable	299	0
Accounts payable (includes $0 and $74 of related parties, respectively)	4,446	1,185
Other accrued liabilities	2,161	959
Deferred revenues	173	43
Total current liabilities	7,079	2,187
Long-term liabilities:
Long-term debt	10,179	0
Senior secured convertible debentures, net	10,804	5,001
Warranty liability	7,042	499
Deferred tax liability	119	0
Other liabilities	62	107
Total liabilities	$ 35,285	$ 7,794
Commitments and Contingencies
Stockholders' equity:
Preferred Stock, $.10 par value, 10,000,000 shares authorized; 6,505 and 11,787 shares issued and outstanding, respectively	$ 1	$ 1
Common Stock, $.001 par value, 150,000,000 shares authorized; 10,283,393 and 6,037,232 shares issued and outstanding, respectively	10	6
Additional paid-in capital	223,315	194,562
Accumulated deficit	(207,240)	(182,293)
Accumulated other comprehensive income	1	0
Total stockholders' equity	16,087	12,276
Total liabilities and stockholders' equity	$ 51,372	$ 20,070

CONSOLIDATED BALANCE SHEETS (Parenthetical) - USD ($) $ in Thousands	Dec. 31, 2015	Dec. 31, 2014
Current Liabilities:
Accounts payable, related parties	$ 0	$ 74
Stockholders' equity:
Preferred stock, par value (in dollars per share)	$ 0.10	$ 0.10
Preferred stock, shares authorized (in shares)	10,000,000	10,000,000
Preferred stock, shares issued (in shares)	6,505	11,787
Preferred stock, shares outstanding (in shares)	6,505	11,787
Common stock, par value (in dollars per share)	$ 0.001	$ 0.001
Common stock, shares authorized (in shares)	150,000,000	150,000,000
Common stock, shares issued (in shares)	10,283,393	6,037,232
Common stock, shares outstanding (in shares)	10,283,393	6,037,232

CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014
CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS [Abstract]
Revenues	$ 18,495	$ 915
Cost of revenues	13,719	4,935
Gross profit (loss)	4,776	(4,020)
Operating expenses:
Engineering and product development	2,029	1,641
Selling and marketing	9,194	3,140
General and administrative	10,028	7,821
Total operating expenses	21,251	12,602
Loss from operations	(16,475)	(16,622)
Other income (expense), net:
Interest expense, net	(10,200)	(2,372)
Change in fair value of warrant liability	1,814	8,103
Gain on sale of assets	0	16
Registration rights liquidated damages	0	(3,420)
Other income, net	33	150
Nonoperating Income (Expense)	(8,353)	2,477
Loss before income taxes	(24,828)	(14,145)
Income tax expense	119	0
Net loss	(24,947)	(14,145)
Deemed dividend related to warrant modification	(2,962)	(1,887)
Net loss attributable to common stockholders	$ (27,909)	$ (16,032)
Basic and diluted net loss per share (in dollars per share)	$ (3.27)	$ (3.03)
Shares used in computing basic and diluted net loss per share (in shares)	8,536,699	5,295,929
Other comprehensive loss:
Foreign currency translation adjustments	$ 1	$ 0
Comprehensive loss	$ (27,908)	$ (16,032)

CONSOLIDATED STATEMENT OF CHANGES IN STOCKHOLDERS' EQUITY - USD ($) $ in Thousands	Convertible Preferred Stock Series A [Member]	Convertible Preferred Stock Series B [Member]	Common Stock [Member]	Additional Paid-In Capital [Member]	Accumulated Deficit [Member]	Accumulated Other Comprehensive Loss [Member]	Total
Beginning balance at Dec. 31, 2013	$ 0	$ 0	$ 5	$ 176,439	$ (168,148)	$ 0	$ 8,296
Beginning balance (in shares) at Dec. 31, 2013	0	0	4,750,159
Issuance of Series A convertible preferred stock and common stock (net of issuance costs of $992)	$ 1	$ 0	$ 0	11,457	0	0	11,458
Issuance of Series A convertible preferred stock and common stock (net of issuance costs of $992) (in shares)	12,300	0	20,270
Issuance of warrants	$ 0	$ 0	$ 0	(5,585)	0	0	(5,585)
Issuance of Series B convertible preferred stock	$ 0	$ 1	$ 0	0	0	0	1
Issuance of Series B convertible preferred stock (in shares)	0	12,300	0
Expenses related to the issuance of Series B convertible preferred stock	$ 0	$ 0	$ 0	(103)		0	(103)
Warrants and beneficial conversion feature issued with senior secured debentures	0	0	0	10,353		0	10,353
Redemption of Series A convertible preferred stock	$ (1)	$ 0	$ 0	0		0	(1)
Redemption of Series A convertible preferred stock (in shares)	(12,300)	0	0
Beneficial conversion feature related to Series B convertible preferred stock	$ 0	$ 1,887	$ 0	(1,887)		0	0
Accretion of discount on Series B convertible preferred stock	0	(1,887)	0	1,887		0	0
Conversion of Series B convertible preferred stock	$ 0	$ 0	$ 0	0		0	0
Conversion of Series B convertible preferred stock (in shares)	0	(513)	200,000
Conversion of senior secured convertible debentures	$ 0	$ 0	$ 1	1,588		0	1,589
Conversion of senior secured convertible debentures (in shares)	0	0	619,490
Exercise of prefunded warrants	$ 0	$ 0	$ 0	0		0	0
Exercise of prefunded warrants (in shares)	0	0	434,325
Stock-based compensation	$ 0	$ 0	$ 0	413		0	413
Stock-based compensation (in shares)	0	0	12,988
Net loss	$ 0	$ 0	$ 0	0	(14,145)	0	(14,145)
Ending balance at Dec. 31, 2014	$ 0	$ 1	$ 6	194,562	(182,293)	0	12,276
Ending balance (in shares) at Dec. 31, 2014	0	11,787	6,037,232
Conversion of Series B convertible preferred stock	$ 0	$ 0	$ 2	(2)	0	0	0
Conversion of Series B convertible preferred stock (in shares)	0	(5,282)	2,059,455
Conversion of senior secured convertible debentures	$ 0	$ 0	$ 2	4,813	0	0	4,815
Conversion of senior secured convertible debentures (in shares)	0	0	2,086,706
Discount on senior secured convertible debentures	$ 0	$ 0	$ 0	27,300	0	0	27,300
Reclassification of warrant liability from stockholders' equity	0	0	0	(5,399)	0	0	(5,399)
Deemed dividend contribution to additional paid-in capital	0	0	0	2,962	0	0	2,962
Deemed dividend distribution from additional paid-in capital	0	0	0	(2,962)	0	0	(2,962)
Warrants issued in connection with debt	0	0	0	321	0	0	321
Registration costs	0	0	0	(33)	0	0	(33)
Other comprehensive income	0	0	0	0	0	1	1
Stock-based compensation	$ 0	$ 0	$ 0	1,753	0	0	1,753
Stock-based compensation (in shares)	0	0	100,000
Net loss	$ 0	$ 0	$ 0	0	(24,947)	0	(24,947)
Ending balance at Dec. 31, 2015	$ 0	$ 1	$ 10	$ 223,315	$ (207,240)	$ 1	$ 16,087
Ending balance (in shares) at Dec. 31, 2015	0	6,505	10,283,393

CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014
Cash Flows From Operating Activities:
Net loss	$ (24,947)	$ (14,145)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	4,051	1,790
Provision for doubtful accounts	20	52
Stock-based compensation	1,753	413
Deferred taxes	119	0
Gain on disposal of property and equipment	0	(16)
Impairment of long-lived assets	920	0
Amortization of debt discount	8,479	1,943
Amortization of deferred financing costs	391	191
Inventory write-offs	4,818	1,084
Change in fair value of warrant liability	(1,814)	(8,103)
Changes in operating assets and liabilities:
Restricted cash	(15)	0
Accounts receivable	(186)	(215)
Inventories	(508)	(784)
Prepaid expenses and other assets	(139)	606
Accounts payable and accrued expenses	542	(241)
Other accrued liabilities	92	0
Other liabilities	(80)	(46)
Deferred revenues	(81)	(238)
Net cash used in operating activities	(6,585)	(17,709)
Cash Flows From Investing Activities:
Lasers placed-in-service, net	(1,689)	0
(Purchases) proceeds on sale of property and equipment	(35)	17
Acquisition of a business, net of cash acquired of $0	(42,500)	0
Net cash (used in) provided by investing activities	(44,224)	17
Cash Flows From Financing Activities:
Proceeds from convertible debentures	32,500	15,000
Repayment of convertible debentures	(103)	0
Proceeds from senior notes	10,000	0
Repayment of senior notes	(10,000)	0
Proceeds from long-term debt	10,500	0
Payments on notes payable	(93)	0
Registration costs	(134)	0
Expenses related to financing	0	(1,115)
Proceeds from private placement/public offerings	0	11,458
Net cash provided by financing activities	42,670	25,343
Effect of exchange rate changes on cash	8	0
Net (decrease)/increase in cash and cash equivalents	(8,131)	7,651
Cash and cash equivalents, beginning of period	11,434	3,783
Cash and cash equivalents, end of period	3,303	11,434
Supplemental information:
Cash paid for interest	1,188	116
Supplemental information of non-cash investing and financing activities
Modification of warrants recorded as a deemed dividend	2,962	0
Beneficial conversion feature recorded as a deemed dividend	0	1,887
Conversion of convertible preferred stock into common stock	5,282	513
Conversion of senior secured convertible debentures into common stock	4,815	1,589
Reclassification of property and equipment to inventory, net	107	0
Reclassification of warrant liability to stockholders' equity	(5,399)	0
Recognition of debt discount and beneficial conversion feature on long-term debt	27,300	10,353
Recognition of warrants issued with term note credit facility as debt discount	321	0
Prepaid insurance financed with notes payable	334	0
Exchange of series A convertible preferred stock for series B convertible preferred stock	0	12,300
Recognition of warrants issued in connection with financings	$ 2,958	$ 5,585

The Company

12 Months Ended

Dec. 31, 2015

The Company [Abstract]

The Company

Note 1

The Company:

Background

STRATA Skin Sciences, Inc. (and its subsidiary) ("STRATA" or "we" or the "Company") (formerly MELA Sciences, Inc.) is a medical technology company dedicated to developing and commercializing innovative products for the diagnosis and treatment of serious dermatological disorders. In June 2015 the Company completed the acquisition of the XTRAC Excimer Laser and the VTRAC excimer lamp businesses from PhotoMedex, Inc. which included a subsidiary in India, PhotoMedex India Ltd. The XTRAC® and VTRAC® products are FDA cleared devices for the treatment of psoriasis, vitiligo and other skin disorders. The purchase price was $42,500 plus the assumption of certain business-related liabilities. Management believes that the cash flow generated by these businesses will be sufficient to finance the Company's operations for the foreseeable future.

The XTRAC is an ultraviolet light excimer laser system utilized to treat psoriasis, vitiligo and other skin diseases. The XTRAC received FDA clearance in 2000 and has since become recognized treatment among dermatologists. The system delivers targeted 308um ultraviolet light to affected areas of skin, leading to psoriasis clearing and vitiligo repigmentation, following a series of treatments. As of December 31, 2015, there were 718 XTRAC systems placed in dermatologists' offices in the United States. The systems generate recurring revenue whereby the XTRAC system is placed in a physician's office for no upfront charge and generates revenue on a per procedure basis. The XTRAC system's use for psoriasis is covered by nearly all major insurance companies, including Medicare. The VTRAC Excimer Lamp system, offered internationally, provides targeted therapeutic efficacy demonstrated by excimer technology with the simplicity of design and reliability of a lamp system.

The financial results of the XTRAC and VTRAC businesses have been included in the results of operations subsequent to June 22, 2015, the date of the acquisition. The assets of the acquired businesses and liabilities assumed have been consolidated as of June 22, 2015. (See Note 2, Acquisition.)

To finance the purchase of the XTRAC and VTRAC businesses, in June 2015 the Company entered into a securities purchase agreement with institutional investors (the "Purchasers") in connection with a private placement (the "2015 Financing"). The Company sold $10,000 aggregate principal amount of Notes bearing interest at 9% per year, with a maturity date of the earlier of 30 days after the Company obtains stockholder approval of stock issuances under the Debentures and the Warrants or November 30, 2015. The matter was approved, by the stockholders' at the Company's annual meeting held September 30, 2015. Accordingly, the Notes matured 30 days from that approval, October 30, 2015. On December 30, 2015, the Company repaid the senior notes payable in full with the proceeds from the long-term credit facility. (See Note 11, Long Term Debt.) The Purchasers of the Notes were issued Warrants to purchase an aggregate of 3.0 million shares of the Company's common stock, having an exercise price of $0.75 per share. The Company also issued $32,500 aggregate principal amount of Senior Secured Convertible Debentures ("Debentures") that, subject to certain ownership limitations and stockholder approval conditions, will be convertible into 43,333,334 shares of common stock at an initial conversion price of $0.75 per share. The Debentures bear interest at the rate of 2.25% per year, and, unless previously converted, will mature on the five-year anniversary of the date of issuance. The Company's obligations under the Notes and Debentures (collectively, the "Debt Securities"), except for $500 of Debentures, are secured by a subordinated lien on all of the Company's assets. Under the terms of the Debentures and the Warrants, the issuances of shares of the common stock, including the Shares upon conversion of the Debentures and upon exercise of the Warrants, are subject to stockholder approval, which was received on September 30, 2015. Effective upon that date, the Company repriced outstanding Warrants held by certain investors to reduce the exercise price to $0.75 per share. (See Note 13, Warrants.)

Liquidity

As of December 31, 2015, the Company had an accumulated deficit of $207,240 and has incurred losses and negative cash flows from operations since inception. To date, the Company has dedicated most of its financial resources to research and development, sales and marketing, and general and administrative expenses.

The Company has been dependent on raising capital from the sale of securities in order to continue to operate and to meet its obligations in the ordinary course of business. The XTRAC and VTRAC businesses, which were acquired on June 22, 2015, have had positive cash flows from operations prior to the acquisition. Management believes that its cash as of December 31, 2015 combined with the anticipated revenues from the sale of the Company's products will be sufficient to satisfy its working capital needs, capital asset purchases, outstanding commitments and other liquidity requirements associated with its existing operations through the first quarter of 2017.

Basis of Presentation:

Accounting Principles

The consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America ("US GAAP").

Principles of Consolidation

The consolidated financial statements include the accounts of the Company and its wholly-owned subsidiary. All significant intercompany balances and transactions have been eliminated in consolidation.

Reclassification

Certain reclassifications from the prior year presentation have been made to conform to the current year presentation. These reclassifications did not have material impact on the Company's equity, net assets, results of operations or cash flows.

Use of Estimates

The preparation of the consolidated financial statements in conformity with accounting principles generally accepted in the US requires management to make estimates and assumptions that affect amounts reported of assets and liabilities at the date of the financial statements and the reported amount of revenues and expenses during the reporting periods. Actual results could differ from those estimates and be based on events different from those assumptions. As of December 31, 2015, the more significant estimates include (1) revenue recognition, including deferred revenues and valuation allowances of accounts receivable, (2) the fair value of assets acquired and liabilities assumed in the business combination, (3) the estimated useful lives of intangible assets and property and equipment, (4) the inputs used in determining the fair value of equity-based awards and (5) the valuation allowance related to deferred tax assets.

Revenue Recognition

The Company recognizes revenues from product sales when the following four criteria have been met: (i) the product has been delivered and the Company has no significant remaining obligations; (ii) persuasive evidence of an arrangement exists; (iii) the price to the buyer is fixed or determinable; and (iv) collection is reasonably assured. Revenues from product sales are recorded net of provisions for expected returns and cash discounts.

The Company ships most of its products FOB shipping point, although from time to time certain customers, for example governmental customers, will be granted FOB destination terms. Among the factors the Company takes into account when determining the proper time at which to recognize revenue are (i) when title to the goods transfers and (ii) when the risk of loss transfers. Shipments to distributors or physicians that do not fully satisfy the collection criteria are recognized when invoiced amounts are fully paid or fully assured and included in deferred revenues until that time.

For revenue arrangements with multiple deliverables within a single, contractually binding arrangement (usually sales of products with separately priced extended warranty), each element of the contract is accounted for as a separate unit of accounting when it provides the customer value on a stand-alone basis and there is objective evidence of the fair value of the related unit.

The Company has two distribution channels for its phototherapy treatment equipment. The Company either (i) places its lasers in a physician's office (at no charge to the physician), and generally charges the physician a fee for an agreed upon number of treatments or (ii) sells its lasers through a distributor or directly to a physician. In some cases, the Company and the customer stipulate to a quarterly or other periodic target of procedures to be performed, and accordingly revenue is recognized ratably over the period.

When the Company places a laser in a physician's office, it generally recognizes revenue based on the number of patient treatments performed, or purchased under a periodic commitment, by the physician. Amounts collected with respect to treatments to be performed through laser-access codes that are sold to physicians free of a periodic commitment, but not yet used, are deferred and recognized as a liability until the physician performs the treatment. Unused treatments remain an obligation of the Company because the treatments can only be performed on Company-owned equipment. Once the treatments are performed, this obligation has been satisfied.

The Company defers substantially all revenue from sales of treatment codes ordered by its customers within the last two weeks of the period in determining the amount of procedures performed by its physician-customers. Management believes this approach closely approximates the actual amount of unused treatments that existed at the end of a period.

Cash and Cash Equivalents

The Company invests its excess cash in highly liquid short-term investments. The Company considers short-term investments that are purchased with an original maturity of three months or less to be cash equivalents. Cash and cash equivalents consisted of cash and money market accounts at December 31, 2015 and 2014.

Accounts Receivable

The majority of the Company's accounts receivable are due from physicians, distributors (international) and other entities in the medical field. Accounts receivable are most often due within 30 to 90 days and are stated at amounts due from customers net of an allowance for doubtful accounts. Accounts outstanding longer than the contractual payment terms are considered past due. The Company determines its allowance for doubtful accounts by considering a number of factors, including the length of time trade accounts receivable are past due, the Company's previous loss history, the customer's current ability to pay its obligation to the Company and available information about their credit risk, and the condition of the general economy and the industry as a whole. The Company writes off accounts receivable when they are considered uncollectible, and payments subsequently received on such receivables are credited to the bad debt expense. The Company does not recognize interest accruing on accounts receivable past due. The allowance for doubtful accounts were $45 and $95 at December 31, 2015 and 2014, respectively.

Inventories

Inventories are stated at the lower of cost or market. Cost is determined to be purchased cost for raw materials and the production cost (materials, labor and indirect manufacturing cost, including sub-contracted work components) for work-in-process and finished goods. For the Company's products, cost is determined on the first-in, first-out method. Throughout the laser manufacturing process, the related production costs are recorded within inventory. Work-in-process is immaterial, given the typically short manufacturing cycle, and therefore is disclosed in conjunction with raw materials.

The Company's equipment for the treatment of skin disorders (e.g. the XTRAC) will either (i) be placed in a physician's office and remain the property of the Company (at which date such equipment is transferred to property and equipment) or (ii) be sold to distributors or physicians directly. The cost to build a laser, whether for sale or for placement, is accumulated in inventory.

Reserves for slow moving and obsolete inventories are provided based on historical experience and product demand. Management evaluates the adequacy of these reserves periodically based on forecasted sales and market trends. As of December 31, 2015 reserves on inventory were $0. During the year ended December 31, 2015, the Company recorded a write-down of $4,818 toward the remaining inventory value of the MelaFind® systems, raw materials and components. (See Note 3, Inventories.)

Property, Equipment and Depreciation

Property and equipment are recorded at cost, net of accumulated depreciation and amortization. Excimer lasers-in-service are depreciated on a straight-line basis over the estimated useful life of five years. For other property and equipment, depreciation is calculated on a straight-line basis over the estimated useful lives of the assets, primarily three to seven years for computer hardware and software, furniture and fixtures, and machinery and equipment. Leasehold improvements are amortized over the lesser of the useful lives or lease terms. Expenditures for major renewals and betterments to property and equipment are capitalized, while expenditures for maintenance and repairs are charged as an expense as incurred. Upon retirement or disposition, the applicable property amounts are deducted from the accounts and any gain or loss is recorded in the condensed consolidated statements of comprehensive loss. Useful lives are determined based upon an estimate of either physical or economic obsolescence or both.

Management evaluates the realizability of property and equipment based on estimates of undiscounted future cash flows over the remaining useful life of the asset. If the amount of such estimated undiscounted future cash flows is less than the net book value of the asset, the asset is written down to fair value. During the year ended December 31, 2015, the Company recorded a write-down of $920 on the remaining net book value of the MelaFind systems that were part of property and equipment (see Impairment of Long-Lived Assets and Intangibles).

Patent Costs and Licensed Technologies

Costs incurred to obtain or defend patents and licensed technologies are capitalized and amortized over the shorter of the remaining estimated useful lives or eight to 12 years. Core technology and product technology were recorded in connection with the asset purchase on June 22, 2015 and are being amortized on a straight-line basis over ten years for core technology and five years for product technology. (See Note 5, Patent and Licensed Technologies).

Other Intangible Assets

Other intangible assets were recorded in connection with the asset purchase on June 22, 2015. The assets that were determined to have definite useful lives are being amortized on a straight-line basis over ten years. Such assets primarily include customer relationships and trademarks. (See Note 7, Other Intangible Assets).

Accounting for the Impairment of Goodwill

Goodwill represents the excess of the purchase price over the fair value of the net tangible and identifiable intangible assets acquired in a business combination. The Company evaluates the carrying value of goodwill annually at the end of the calendar year and also between annual evaluations if events occur or circumstances change that would more likely than not reduce the fair value of the reporting unit to which goodwill was allocated to below its carrying amount. Such circumstances could include, but are not limited to: (1) a significant adverse change in legal factors or in business climate, (2) unanticipated competition, or (3) an adverse action or assessment by a regulator. When evaluating goodwill for impairment, we may first perform an assessment qualitatively whether it is more likely than not that a reporting unit's carrying amount exceeds its fair value, referred to as a "step zero" approach. If, based on the review of the qualitative factors, we determine it is not more likely than not that the fair value of a reporting unit is less than its carrying value, we would bypass the two-step impairment test. If we conclude that it is more likely than not that a reporting unit's fair value is less than its carrying amount, we would perform the first step ("step one") of the two-step impairment test. Step 1 compares the fair value of the Group's reporting units to which goodwill was allocated to their carrying values. If the fair value of the reporting unit exceeds its carrying value, no further analysis is necessary. The reporting unit fair value is based upon consideration of various valuation methodologies, including guideline transaction multiples, multiples of current earnings, and projected future cash flows discounted at rates commensurate with the risk involved. If the carrying amount of the reporting unit exceeds its fair value, Step 2 must be completed to quantify the amount of impairment. Step 2 calculates the implied fair value of goodwill by deducting the fair value of all tangible and intangible assets, excluding goodwill, of the reporting unit, from the fair value of the reporting unit as determined in Step 1. The implied fair value of goodwill determined in this step is compared to the carrying value of goodwill. If the implied fair value of goodwill is less than the carrying value of goodwill, an impairment loss, equal to the difference, is recognized. There was no impairment of goodwill as of December 31, 2015.

Impairment of Long-Lived Assets and Intangibles

Long-lived assets, such as property and equipment, and definite-lived intangibles subject to amortization, are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability of assets to be held and used is measured by a comparison of the carrying amount of an asset to the undiscounted cash flows attributable to the asset. If the carrying amount of an asset exceeds its undiscounted cash flows, an impairment charge is recognized in the amount by which the carrying amount of the asset exceeds its fair value of the asset. During the year December 31, 2015 the Company recorded a write-down of $920 on the remaining net book value of the MelaFind systems that were part of property and equipment. Assets to be disposed of are separately presented in the balance sheet and reported at the lower of the carrying amount or fair value less costs to sell, and are no longer depreciated. The assets and liabilities of a disposed group classified as discontinued operations are presented separately in the appropriate asset and liability sections of the balance sheet. There were no impairments recorded as of December 31, 2015 related to any of the Company's intangible assets.

Functional Currency

The currency of the primary economic environment in which the operations of the Company are conducted is the US dollar ("$" or "dollars"). Thus, the functional currency of the Company is the dollar except the operations of its foreign subsidiary, which is conducted in its local currency the Indian Rupee (INR). Substantially all of the Company's revenues are derived in dollars or in other currencies linked to the dollar. Purchases of most materials and components are carried out in, or linked to the dollar.

For foreign currency transactions included in the statement of comprehensive loss, the exchange rates applicable to the relevant transaction dates are used. Transaction gains or losses arising from changes in the exchange rates used in the translation of such balances are carried to financing income or expenses.

Assets and liabilities of the foreign subsidiary, whose functional currency is its local currency, are translated from its functional currency to U.S. dollars at the balance sheet date exchange rate. Income and expense items are translated at the average rate of exchange prevailing during the year. Translation adjustments are reflected in the consolidated balance sheets as a component of accumulated other comprehensive loss.

Fair Value Measurements

The Company measures and discloses fair value in accordance with Financial Accounting Standards Board ("FASB") Accounting Standards Codification 820, Fair Value Measurements and Disclosures ("ASC Topic 820"). ASC Topic 820 defines fair value, establishes a framework and gives guidance regarding the methods used for measuring fair value, and expands disclosures about fair value measurements. Fair value is an exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. As such, fair value is a market-based measurement that should be determined based on assumptions that market participants would use in pricing an asset or liability. As a basis for considering such assumptions there exists a three-tier fair-value hierarchy, which prioritizes the inputs used in measuring fair value as follows:

	•	Level 1 – unadjusted quoted prices are available in active markets for identical assets or liabilities that the Company has the ability to access as of the measurement date.
	•	Level 2 – pricing inputs are other than quoted prices in active markets that are directly observable for the asset or liability or indirectly observable through corroboration with observable market data.

•

Level 3 – pricing inputs are unobservable for the non-financial asset or liability and only used when there is little, if any, market activity for the non-financial asset or liability at the measurement date. The inputs into the determination of fair value require significant management judgment or estimation. Fair value is determined using comparable market transactions and other valuation methodologies, adjusted as appropriate for liquidity, credit, market and/or other risk factors

This hierarchy requires the Company to use observable market data, when available, and to minimize the use of unobservable inputs when determining fair value.

The Company's recurring fair value measurements at December 31, 2015 and 2014 are as follows:

	Fair Value as of December 31, 2015		Quoted Prices in Active Markets for Identical Assets (Level 1)		Significant other Observable Inputs (Level 2)		Significant Unobservable Inputs (Level 3)
Liabilities:
Warrant liability (Note 13)	$	7,042	$	-	$	-	$	7,042

	Fair Value as of December 31, 2014		Quoted Prices in Active Markets for Identical Assets (Level 1)		Significant other Observable Inputs (Level 2)		Significant Unobservable Inputs (Level 3)
Liabilities:
Warrant liability (Note 13)	$	499	$	-	$	-	$	499

The fair value of cash and cash equivalents are based on their respective demand value, which are equal to the carrying value. The fair value of derivative warrant liabilities is estimated using option pricing models that are based on the individual characteristics of the Company's warrants, preferred and common stock, the derivative warrant liability on the valuation date as well as assumptions for volatility, remaining expected life, risk-free interest rate and, in some cases, credit spread. The derivative warrant liabilities are the only recurring Level 3 fair value measures. The carrying value of all other short-term monetary assets and liabilities is estimated to be approximate to their fair value due to the short-term nature of these instruments. The Company assessed its convertible debentures and long-term debt and determined that the fair value of total debt was $15,958 as of December 31, 2015. As of December 31, 2014 the fair value of total debt approximated the recorded value of $5,001.

Several of the warrants have non-standard terms as they relate to a fundamental transaction and require a net-cash settlement upon change in control of the Company and other warrants contain full ratchet provisions that reduce the exercise price of the warrants in the event of a transaction resulting in the issuance of equity below the current price of the warrants. Therefore these warrants are classified as derivatives. These warrants have been recorded at their fair value using a binomial option pricing model and will be recorded at their respective fair value at each subsequent balance sheet date. See Note 13, Warrants, for additional discussion.

Accrued Warranty Costs

The Company offers a standard warranty on product sales generally for a one to two-year period, however, the Company has offered longer warranty periods, ranging from three to four years, in order to meet competition or meet customer demands. The Company provides for the estimated cost of the future warranty claims on the date the product is sold. Total accrued warranty is included in Other Accrued Liabilities and Other liabilities on the balance sheet. The activity in the warranty accrual during the year ended December 31, 2015 is summarized as follows:

	December 31, 2015

Accrual at beginning of year	$	48
Acquired in asset purchase		265
Additions charged to warranty expense		98
Expiring warranties/claimed satisfied		(185	)
Total		226
Less: current portion		(168	)
	$	58

Product Development Costs

Costs of research, new product development and product redesign are charged to expense as incurred in engineering and product development.

Advertising Costs

Advertising costs are charged to expenses as incurred. Advertising expenses amounted to approximately $2,500 and $0 for the years ended December 31, 2015 and 2014, respectively.

Income Taxes

The Company accounts for income taxes using the asset and liability method. Under this method, deferred tax assets and liabilities are determined based on differences between the financial reporting and tax basis of assets and liabilities and are measured using enacted tax rates and laws that are expected to be in effect when the differences reverse. Any resulting net deferred tax assets are evaluated for recoverability and, accordingly, a valuation allowance is provided when it is more likely than not that all or some portion of the deferred tax asset will not be realized.

The Company accounts for uncertain tax positions in accordance with an amendment to ASC Topic 740-10, Income Taxes (Accounting for Uncertainty in Income Taxes), which clarified the accounting for uncertainty in tax positions. This amendment provides that the tax effects from an uncertain tax position can be recognized in the financial statements only if the position is "more-likely-than-not" to be sustained were it to be challenged by a taxing authority. The assessment of the tax position is based solely on the technical merits of the position, without regard the likelihood that the tax position may be challenged. If an uncertain tax position meets the "more-likely-than-not" threshold, the largest amount of tax benefit that is more than 50% likely to be recognized upon ultimate settlement with the taxing authority is recorded.

Concentration of credit risks

Financial instruments which subject the Company to concentrations of credit risk consist primarily of cash and cash equivalents and accounts receivable. The carrying amounts of these instruments approximate fair value due to their short-term nature. The Company deposits cash and cash equivalents in major financial institutions in the US. The Company performs periodic evaluations of the relative credit standing of these institutions. The Company is of the opinion that the credit risk in respect of these balances is immaterial. In addition, the Company performs an ongoing credit evaluation and establishes an allowance for doubtful accounts based upon factors surrounding the credit risk of customers (see also Accounts receivable above).

Most of the Company's sales are generated in North America, to a large number of customers. Management periodically evaluates the collectability of the trade receivables to determine the amounts that are doubtful of collection and determine a proper allowance for doubtful accounts. Accordingly, the Company's trade receivables do not represent a substantial concentration of credit risk.

Earnings Per Share

Basic net loss per common share excludes dilution for potentially dilutive securities and is computed by dividing net loss attributable to common stockholders by the weighted average number of common shares outstanding during the period. Diluted net loss per common share gives effect to dilutive options, warrants and other potential common shares outstanding during the period and their potential diluted effect is considered using the treasury method.

For the years ended December 31, 2015 and 2014, diluted net loss per common share is equal to the basic net loss per common share since all potentially dilutive securities are anti-dilutive. The loss on the change in fair value of the warrant liability would be considered in the diluted earnings per share calculation and was deemed to be antidilutive. Potential common stock equivalents outstanding as of December 31, 2015 and 2014 consist of common stock equivalents of common stock purchase warrants, senior secured convertible debentures, convertible preferred stock and common stock options, which are summarized as follows:

	December 31,
	2015	2014
Common stock equivalents of convertible debentures	46,435,127	5,228,465
Common stock purchase warrants	16,729,362	13,078,920
Common stock equivalents of convertible preferred stock	2,535,866	4,595,321
Common stock options	2,684,352	1,308,835
Total	68,384,707	24,211,541

Stock-Based Compensation

The Company accounts for stock-based compensation in accordance with ASC Topic 718, Compensation – Stock Compensation. Under the fair value recognition provision of this statement, share-based compensation cost is measured at the grant date based on the fair value of the award that is ultimately expected to vest and is recognized as operating expense over the applicable vesting period of the stock award using the graded vesting method.

Adoption of New Accounting Standards

In April 2014, the Financial Accounting Standards Board ("FASB") issued Accounting Standard Update 2014-08, Presentation of Financial Statements (Topic 205) and Property, Plant, and Equipment (Topic 360): Reporting Discontinued Operations and Disclosures of Disposals of Components of an Entity ("ASU 2014-08").

The amendments in ASU 2014-08 change the criteria for reporting discontinued operations while enhancing disclosures in this area. Under the new guidance, only disposals representing a strategic shift in operations should be presented as discontinued operations. Those strategic shifts should have a major effect on the organization's operations and financial results. In addition, the new guidance requires expanded disclosures about discontinued operations that will provide financial statement users with more information about the assets, liabilities, income, and expenses of discontinued operations.

The provisions of ASU 2014-08 were required to be applied in a prospective manner to disposals or classifications as held for sale components of an entity that occur with annual periods beginning on or after December 15, 2014 and interim periods within those years.

The adoption of ASU 2014-08 did not have a material impact on the Company's consolidated results of operations and financial condition.

Recently Issued Accounting Standards

In February 2016, the FASB issued ASU 2016-02, Leases, This statement requires lessees to present right-of-use assets and lease liabilities on the balance sheet. The standard is effective for public companies for annual periods beginning after December 15, 2018, including interim periods within those fiscal years. The Company is currently evaluating the effect the guidance will have on its financial condition and results of operations.

In November 2015, the FASB issued ASU 2015-17, Income Taxes, Balance Sheet Classification of Deferred Taxes topic of the Codification. This standard requires all deferred tax assets and liabilities to be classified as non-current on the balance sheet instead of separating deferred taxes into current and non-current amounts. In addition, valuation allowance allocations between current and non-current deferred tax assets are no longer required because those allowances also will be classified as non-current. This standard is effective for public companies for annual periods beginning after December 15, 2016. The Company's deferred tax assets is provided with full valuation allowance as of December 31, 2015. As such, the Company does not expect that this standard will have a significant impact upon adoption.

In September 2015, the FASB issued ASU No. 2015-16, "Business Combinations (Topic 805): Simplifying the Accounting for Measurement-Period Adjustments." The amendments in ASU 2015-16 require that an acquirer recognize adjustments to estimated amounts that are identified during the measurement period in the reporting period in which the adjustment amounts are determined, rather than retrospectively adjusting amounts previously reported. The amendments require that the acquirer record, in the same period's financial statements, the effect on earnings of changes in depreciation, amortization, or other income effects, if any, as a result of the change to the estimated amounts, calculated as if the accounting had been completed at the acquisition date. Effective for public business entities for fiscal years beginning after December 15, 2015, including interim periods within those fiscal years. The amendments should be applied prospectively to adjustments to provisional amounts that occur after the effective date with earlier application permitted for financial statements that have not been issued. The Company does not believe the adoption of this ASU will have a significant impact on the condensed consolidated financial statements.

In July, 2015, The FASB issued Accounting Standards Update No. 2015-11, Simplifying the Measurement of Inventory (Topic 330) ("ASU 2015-11").

ASU 2015-11 outlines that inventory within the scope of its guidance be measured at the lower of cost and net realizable value. Inventory measured using last-in, first-out (LIFO) are not impacted by the new guidance. Prior to the issuance of ASU 2015-11, inventory was measured at the lower of cost or market (where market was defined as replacement cost, with a ceiling of net realizable value and floor of net realizable value less a normal profit margin).

For a public entity, the amendments in ASU 2015-11 are effective, in a prospective manner, for annual reporting periods beginning after December 15, 2016, including interim periods within that reporting period (the first quarter of fiscal year 2017 for the Company). Early adoption is permitted as of the beginning of an interim or annual reporting period.

The Company is in the process of assessing the impact, if any, of ASU 2015-11 on its consolidated financial statements.

In May 2014, The FASB issued Accounting Standards Update No. 2014-09, Revenue from Contracts with Customers (Topic 606) ("ASU 2014-09").

ASU 2014-09 outlines a single comprehensive model to use in accounting for revenue arising from contracts with customers and supersedes most current revenue recognition guidance, including industry-specific guidance. ASU 2014-09 also requires entities to disclose sufficient information, both quantitative and qualitative, to enable users of financial statements to understand the nature, amount, timing, and uncertainty of revenue and cash flows arising from contracts with customers.

An entity should apply the amendments in this ASU using one of the following two methods: 1. Retrospectively to each prior reporting period presented with a possibility to elect certain practical expedients, or, 2. Retrospectively with the cumulative effect of initially applying ASU 2014-09 recognized at the date of initial application. If an entity elects the latter transition method, it also should provide certain additional disclosures.

For a public entity, the amendments in ASU 2014-09 were to be effective for annual reporting periods beginning after December 15, 2016, including interim periods within that reporting period. In July 2015, the FASB voted for a one year deferral of the effective date of ASU 2014-09 and issued an exposure draft. The new guidance will be effective for annual and interim periods beginning on or after December 15, 2017. Early application is not permitted. The Company is currently assessing the impact that adopting this new accounting guidance will have on its consolidated financial statements and footnote disclosures.

In August 2014, the FASB issued Accounting Standards Update No. 2014-15, Presentation of Financial Statements—Going Concern (Subtopic 205-40): Disclosure of Uncertainties about an Entity's Ability to Continue as a Going Concern ("ASU 2014-15"). ASU 2014-15 provides guidance on management's responsibility in evaluating whether there are conditions or events, considered in the aggregate, that raise substantial doubt about the entity's ability to continue as a going concern within one year after the date that the financial statements are issued (or within one year after the date that the financial statements are available to be issued when applicable). ASU 2014-15 also provides guidance related to the required disclosures as a result of management evaluation. The amendments in ASU 2014-15 are effective for the annual period ending after December 15, 2016, and for annual periods and interim periods thereafter. Early application is permitted. The Company is currently evaluating the new guidance to determine the impact the adoption of this guidance will have on the Company's results of operations, cash flows or financial condition.

In April 2015, the Financial Accounting Standards Board ("FASB") issued Accounting Standards Update ("ASU") No. 2015-03, "Simplifying the Presentation of Debt Issuance Costs" (Subtopic 835-30). ASU No. 2015-03 provides guidance that will require debt issuance costs related to a recognized debt liability to be presented in the balance sheet as a direct deduction from the carrying amount of that debt liability, in the same manner as debt discounts, rather than as an asset. The standard is effective for reporting periods beginning after December 15, 2015 and early adoption is permitted. The Company adopted this ASU effective January 1, 2016. Upon adoption of this guidance $328 of deferred financing costs will be reclassified against long-term debt and $966 will be reclassified against convertible debentures.

Acquisition

12 Months Ended

Dec. 31, 2015

Acquisition [Abstract]

Acquisition

Note 2

Acquisition:

On June 22, 2015, the Company entered into an asset purchase agreement (the "Asset Purchase Agreement") with PhotoMedex Inc. and PhotoMedex Technology, Inc. pursuant to which the Company has purchased the XTRAC and VTRAC laser businesses from PhotoMedex, Inc. (the "Asset Purchase") for $42,528 in cash and assumed certain business-related liabilities. The purchased assets include all of the accounts receivable, inventory and fixed and intangible assets of the business.

The fair value of the assets acquired and liabilities assumed were based on management estimates. The significant intangible assets to be recognized in the valuation are core and product technologies, tradenames and customer relationships. The estimated useful lives over which these assets will be amortized, utilizing the straight line method, are five years for product technologies and ten years for core technologies, tradenames and customer relationships. The following allocation of the aggregate fair value is preliminary and subject to adjustment based on the fair value of the assets acquired and the liabilities assumed. The Company estimated fair value of the intangibles and lasers placed in service was based on the income approach which estimated cash flow that utilize appropriate discount and capitalization rates and available market information. Estimates of future cash flows are based on a number of factors including the historical operating results, known trends and specific market and economic conditions. The fair value of the Company's remaining fixed assets was estimated based on the cost approach which estimated the cost to replace.

Current assets	$	7,233
Property, plant and equipment		14,340
Identifiable intangible assets		16,100
Other assets		45
Total assets assumed		37,718

Current liabilities		(3,945	)
Note payable		(57	)
Other long term liabilities		(116	)
Total liabilities assumed		(4,118	)

Net assets acquired	$	33,600

The purchase price exceeded the fair value of the net assets acquired by $8,928, which was recorded as goodwill.

The consolidated results of operations do not include any revenues or expenses related to XTRAC and VTRAC businesses on or prior to June 22, 2015, the date of the asset purchase. The Company's unaudited pro-forma results for the year ended December 31, 2015 and 2014 summarize the combined results in the following table, assuming the asset purchase had occurred on January 1, 2014 and after giving effect to the acquisition adjustments, including amortization of the tangible and long-lived intangible assets acquired in the transaction:

	Year Ended December 31,
	2015			2014
	(unaudited)			(unaudited)

Net revenues	$	33,163		$	31,497
Net loss attributable to common shareholders	$	(34,252	)	$	(26,954	)
Net loss per basic and diluted share:	$	(4.01	)	$	(5.09	)
Shares used in calculating net loss per basic and diluted share:		8,536,699			5,295,929

These unaudited pro-forma results have been prepared for comparative purposes only and do not purport to be indicative of the results of operations which would have actually resulted had the acquisition occurred on January 1, 2014, nor to be indicative of future results of operations.

- Definition

The entire disclosure for a business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities. The disclosure may include leverage buyout transactions (as applicable).

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 10
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=56956515&loc=d3e1497-128463

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=56956515&loc=d3e1490-128463

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=56956515&loc=d3e1392-128463

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 30
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=35744584&loc=d3e7008-128479

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=56956515&loc=d3e1486-128463

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 30
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=35744584&loc=d3e6927-128479

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 20
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=56956791&loc=d3e4845-128472

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 10
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=56956515&loc=d3e1500-128463

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 10
-Section 50
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=56956515&loc=d3e1524-128463

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 30
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=35744584&loc=d3e7000-128479

Reference 11: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 20
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=56956791&loc=d3e4922-128472

Reference 12: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 20
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=56956791&loc=d3e4934-128472

Reference 13: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 20
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=56956791&loc=d3e4926-128472

Reference 14: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=56956515&loc=d3e1383-128463

Reference 15: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 30
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=35744584&loc=d3e6996-128479

+ Details

Inventories

12 Months Ended

Dec. 31, 2015

Inventories [Abstract]

Inventories, net

Note 3

Inventories:

	December 31, 2015		December 31, 2014

Raw materials and work in progress	$	3,706	$	2,553
Finished goods		422		4,131
Total inventories		4,128		6,684
Reserve for obsolete inventory		-		(870	)
Reserve for inventory repairs		-		(539	)
	$	4,128	$	5,275

Work-in-process is immaterial, given the Company's typically short manufacturing cycle, and therefore is disclosed in conjunction with raw materials. During the year ended December 30, 2015 the Company initiated plans to develop an updated version of the MelaFind system and, accordingly, determined that a majority of its existing inventory of MelaFind systems and related parts exceeded its requirements. As a result, the Company wrote-off the excess and obsolete MelaFind inventories of $5,688, including $870 previously reserved. In addition, as of December 31, 2014 the Company carried a repair reserve of $539 for the estimated cost to restore its MelaFind units to sellable condition, which was also eliminated with the write-off of the excess and obsolete MelaFind inventory.

Property and Equipment, net

12 Months Ended

Dec. 31, 2015

Property and Equipment, net [Abstract]

Property and Equipment, net

Note 4

Property and Equipment, net:

	December 31, 2015			December 31, 2014

Lasers placed-in-service	$	15,783		$	-
MelaFind systems		-			3,193
Equipment, computer hardware and software		1,219			1,084
Furniture and fixtures		2,080			1,969
Leasehold improvements		931			906
		20,012			7,152
Accumulated depreciation and amortization		(6,161	)		(5,191	)
Property and equipment, net	$	13,851		$	1,961

Depreciation and related amortization expense was $3,141 and $1,785 for the year ended December 31, 2015 and 2014, respectively. During the second quarter of 2015, the Company evaluated the future cash flows of the MelaFind devices with remaining net book value, determined there was an impairment and recorded an impairment charge of $920.

Other Intangible Assets

12 Months Ended

Dec. 31, 2015

Other Intangible Assets [Abstract]

Other Intangible Assets

Note 7

Other Intangible Assets:

Set forth below is a detailed listing of other definite-lived intangible assets:

	December 31, 2015

Customer relationships	$	6,900
Tradenames		1,500
		8,400
Accumulated amortization		(420	)
Other intangible assets, net	$	7,980

Related amortization expense was $420 for the year ended December 31, 2015. There was no related amortization expense for the year ended December 31, 2014. Customer Relationships embody the value to the Company of relationships that PhotoMedex, for the XTRAC and VTRAC products, had formed with its customers. Trademarks include the tradenames and various trademarks associated with the products (e.g. "XTRAC" and "VTRAC"). Amortization of these intangibles is on a straight-line basis over 10 years for each of the customer relationships and tradenames. There were no other intangible assets at December 31, 2014

Estimated amortization expense for the above amortizable intangible assets for the future periods is as follows:

2016	$	840
2017		840
2018		840
2019		840
2020		840
Thereafter		3,780
Total	$	7,980

Senior Notes Payable

12 Months Ended

Dec. 31, 2015

Senior Notes Payable [Abstract]

Senior Notes Payable

Note 9

Senior Notes Payable:

On June 22, 2015, the Company entered into a Securities Purchase Agreement (the "Securities Purchase Agreement") and related financing documents with entities affiliated with existing institutional investors in the Company providing for the issuance of $42,500 aggregate principal amount (the "Financing") of senior secured notes (the "Notes"), senior secured convertible debentures, except for $500 of Debentures, (the "June 2015 debentures") and warrants (the "June 2015 Warrants") to purchase 3,000,000 shares of common stock at an exercise price of $0.75 per share. The Company sold $10,000 aggregate principal amount of Notes bearing interest at 9% per year with a maturity date of the earlier of 30 days after the Company obtains stockholder approval of stock issuances under the Debentures and the Warrants or November 30, 2015. The June 2015 Debentures are discussed further in Note 10, Convertible Debentures, below. The proceeds of the Financing were used to pay the purchase price of the assets acquired under the Asset Purchase Agreement.

Under the terms of the June 2015 Warrants, the issuances of shares of the common stock upon exercise of the Warrants were subject to stockholder approval of such issuances and an amendment to the Company's certificate of incorporation to increase the Company's authorized shares of common stock. The matter was approved by the stockholders at the Company's annual meeting held September 30, 2015. Accordingly, the Notes matured 30 days from that approval, October 30, 2015. On December 30, 2015, the Company repaid the senior notes payable in full with the proceeds from the long-term credit facility. (See Note 11, Long Term Debt.)

The June 2015 Warrants contain anti-dilution provisions that allow for downward exercise price adjustments in certain situations. The warrants were treated as a derivative liability (see Note 13, Warrants) and a discount to the Notes and the discount was amortized under the effective interest method over the repayment term of 5 months. The discount of $2,958 was fully amortized through December 31, 2015.

The Company computed the value of the warrants using the binomial method. The key assumptions used to value the warrants are as follows:

	June 22, 2015	December 31, 2015

Number of shares underlying warrants	3,000,000	3,000,000
Exercise price	$0.75	$0.75
Share price	$1.38	$1.11
Fair value of warrants	$2,959	$1.807
Probability of stockholder approval	80.0%	100.0%
Volatility	90.0%	50.0%
Risk-free interest rate	1.62%	1.65%
Expected dividend yield	0%	0%
Expected warrant life	5 years	4.48 years

Convertible Debentures

12 Months Ended

Dec. 31, 2015

Convertible Debentures [Abstract]

Convertible Debentures

Note 10

Convertible Debentures:

In the following table is a summary of the Company's convertible debentures.

	December 31, 2015		December 31, 2014

Senior secured 2.25% convertible debentures, net of unamortized debt discount of $26,267	$	6,011	$	-
Senior secured 4% convertible debentures, net of unamortized debt discount of $3,922 and $8,410, respectively		4,793		5,001
Total convertible debt	$	10,804	$	5,001

The Company issued $32,500 aggregate principal amount of Debentures (June 2015 Debentures) that, subject to certain ownership limitations and stockholder approval conditions, will be convertible into 43,333,334 shares of Company common stock at an initial conversion price of $0.75 per share. The Debentures bear interest at the rate of 2.25% per year, and, unless previously converted, will mature on the five-year anniversary of the date of issuance, June 22, 2020. Under the terms of the June 2015 Debentures and the June 2015 Warrants (noted above), the issuances of shares of the common stock upon conversion of the June 2015 Debentures and upon exercise of the Warrants were subject to stockholder approval of such issuances and an amendment to the Company's certificate of incorporation to increase the Company's authorized shares of common stock. The Company received stockholder approval for these proposals, at the annual stockholders meeting held September 30, 2015.

The June 2015 Debentures include a beneficial conversion feature valued at $27,300 that was recorded as a discount to the debentures. On the date of issuance the beneficial conversion feature value was calculated as the difference resulting from subtracting the conversion price of $0.75 from $1.38, the opening market value of the Company's common stock following the announcement of the transaction, multiplied by the number of common shares into which the June 2015 Debentures are convertible. This discount is being amortized over the five year life of the June 2015 Debentures using the effective interest method. The embedded conversion feature contains an anti-dilution provision that allows for downward exercise price adjustments in certain situations. The embedded conversion feature was not bifurcated as it did not meet all of the elements of a derivative.

On July 21, 2014, the Company entered into a definitive Securities Purchase Agreement (the "Purchase Agreement") with institutional investors (the "Investors") providing for the issuance of Senior Secured Convertible Debentures in the aggregate principal amount of $15,000, due, subject to the terms therein, in July 2019 (the "July 2014 Debentures"), and warrants (the "July 2014 Series A Warrants") to purchase up to an aggregate of 6,198,832 shares of common stock, $0.001 par value per share, at an exercise price of $2.45 per share expiring in July 2019. The July 2014 Debentures bear interest at an annual rate of 4%, payable quarterly or upon conversion into shares of common stock. The Debentures are convertible at any time into an aggregate of 5,847,955 shares of common stock at an initial conversion price of $2.565 per share. The Company's obligations under the July 2014 Debentures are secured by a first priority lien on all of the Company's intellectual property pursuant to the terms of a security agreement ("Security Agreement") dated July 21, 2014 among the Company and the Investors. In connection with the Purchase Agreement, the Company entered into a Registration Rights Agreement with the Investors pursuant to which the Company was obligated to file a registration statement to register for resale the shares of Common Stock issuable upon conversion of the Series B Preferred Stock (See Note 13, Warrants) and Debentures and upon exercise of the Warrants. Under the terms of the Registration Rights Agreement, the Company filed a registration statement on August 19, 2014, which was declared effective by the SEC on October 20, 2014 (File No. 333-198249). Proceeds from the Debentures were used for general working capital purposes.

For financial reporting purposes, the $15,000 funded by the Investors on July 21, 2014 was allocated first to the fair value of the obligation to issue the Warrants, amounting to $5,296, then to the intrinsic value of the beneficial conversion feature on the July 2014 Debentures of $4,565. The balance was further reduced by the fair value of warrants issued to the placement agent for services rendered of $491, resulting in an initial carrying value of the Debentures of $4,647. The initial debt discount on the July 2014 Debentures totaled $10,353 and is being amortized using the effective interest method over the five year life of the July 2014 Debentures.

During the year ended December 31, 2015, the investors converted debentures amounting to $4,593 into 1,790,671 shares of common stock for the July 2014 note and $222 into 296,035 shares of common stock for the June 2015 note. The debt discount and deferred financing cost adjustment resulting from the conversions increased interest expense by $3,601 for the year ended December 31, 2015.

As a condition of the new note facility (See Note 11, Long-term Debt below) the Debentures from both the 2014 and 2015 financings were amended. The Debentures holders' first priority lien was subordinated to the new term note facility. Additionally, as a condition of the term note facility, the maturity date of both Debentures was extended to June 30, 2021. The Company evaluated the modifications to determine if there was an extinguishment of debt. Based on the valuation, the discounted cash flows did not change by more than 10%, thus they were treated as a modification.

As of December 31, 2015, the total outstanding amount of Debentures was $40,993.

Long-term Debt

12 Months Ended

Dec. 31, 2015

Long-term Debt [Abstract]

Long-term Debt

Note 11

Long-term Debt:

Term-Note Credit Facility

On December 30, 2015, the Company entered into a $12,000 credit facility pursuant to a Credit and Security Agreement (the "Agreement") and related financing documents with MidCap Financial Trust ("MidCap") and the lenders listed therein. Under the Agreement, the credit facility may be drawn down in two tranches, the first of which was drawn for $10,500 on December 30, 2015. The proceeds of this first tranche were used to repay $10,000 principal amount of short-term senior secured promissory notes (See Note 9, Senior Notes Payable), plus associated interest, loan fees and expenses. The second tranche was drawn for $1,500 on January 29, 2016. The Company's obligations under the credit facility are secured by a first priority lien on all of the Company's assets. This credit facility includes both financial and non-financial covenants, including a minimum net revenue covenant, beginning in January 2016. The Company's existing debentures from its 2014 and 2015 financings were amended as a condition of this new term note facility, including subordination agreements and maturity extensions. As of December 31, 2015 the net balance of long-term debt is $10,179

In connection with the issuance of the Term Note the Company issued MidCap (and the lenders) a warrant to purchase 650,442 shares of the Company's common stock for an exercise price of $1.13. The warrant is exercisable at any time on or prior to the fifth anniversary of its issue date. The warrants are treated as a discount to the debt and are accreted under the effective interest method over the repayment term of 60 months. The Company has accounted for these warrants as equity instruments since there is no option for cash or net-cash settlement when the warrants are exercised and since they are indexed to the Company's common stock. The Company computed the value of the warrants using the Black-Scholes method. The key assumptions used to value the warrants are as follows:

		December 30, 2015

Number of shares underlying warrants		650,442
Exercise price		$1.13
Stock price on date of issuance		$1.11
Fair value of warrants		$321,045
Volatility		50.0%
Risk-free interest rate		1.8%
Expected dividend yield		0%
Expected warrant life		5 years

During December 2015 the Company changed its method of calculating expected volatility that is used in its fair value measurements and measurements of share based compensation cost. The new method estimates expected volatility by using a combination of the Company's historical volatility since June 22, 2015, the acquisition date of the XTRAC and VTRAC businesses, plus the historical volatility of stocks of similar publicly-traded companies for a period matching the expected term of the underlying instrument. The Company believes that this method provides for a better estimate of future volatility because of the significant change to the overall Company resulting from the acquisition of the XTRAC and VTRAC businesses on June 22, 2015. The Company had historically calculated expected volatility based solely upon the historical volatility of the Company's daily closing stock price. Had the Company utilized the historical method of calculating volatility, the resulting volatility would have been 77% and the fair value of these warrants would have been $439 at December 31, 2015.

Commitments and Contingencies

12 Months Ended

Dec. 31, 2015

Commitments and Contingencies [Abstract]

Commitments and Contingencies

Note 12

Commitments and Contingencies:

Leases

The Company has entered into various non-cancelable operating lease agreements for real property and three minor operating leases for personal property. These arrangements expire at various dates through 2018. Rent expense was $748 and $445 for the years ended December 31, 2015 and 2014, respectively. The future annual minimum payments under these leases, relating to our continuing operations are as follows:

Year Ending December 31,
2016	$	861
2017		205
Thereafter		19
Total	$	1,085

Warrants

12 Months Ended

Dec. 31, 2015

Warrants [Abstract]

Warrants

Note 13

Warrants:

The Company accounts for warrants that have provisions that protect holders from a decline in the issue price of its common stock (or "down-round" provisions) as liabilities instead of equity. Down-round provisions reduce the exercise or conversion price of a warrant or convertible instrument if a company either issues equity shares for a price that is lower than the exercise or conversion price of those instruments or issues new warrants or convertible instruments that have a lower exercise or conversion price. Net settlement provisions allow the holder of the warrant to surrender shares underlying the warrant equal to the exercise price as payment of its exercise price, instead of physically exercising the warrant by paying cash. The Company evaluated whether warrants to acquire its common stock contain provisions that protect holders from declines in the stock price or otherwise could result in modification of the exercise price and/or shares to be issued under the respective warrant agreements based on a variable that is not an input to the fair value of a "fixed-for-fixed" option. In connection with the Senior secured notes (see Note 9, Senior Notes Payable), the Company issued warrants to purchase 3,000,000 shares of common stock. These warrants were classified as liabilities and had an initial fair value of $2,958. See the table in Note 9 for the assumptions used.

As approved by the stockholders on September 30, 2015, the Company modified the terms of warrants held by the investors that participated in the June 2015 Debentures in excess of $5 million, which included reducing the exercise price of such warrants to $0.75 and adding down-round price protection provisions. These warrants had previously been classified and recorded in stockholders' equity. As a result of the modification these warrants now meet the definition of a derivative. The fair value of these warrants as of September 30, 2015 was $5,399 and have been reclassified to a warrant liability. As a result of the modification, the Company recorded a deemed dividend related to these warrants of $2,962, which was determined as the difference between the fair value of these warrants immediately before the modification and immediately after. The Company used the binomial method to value the warrants. (See assumptions used in the table below.) The following is a listing of the warrants modified:

Issue date	# of warrants	Original Exercise Price	New Exercise Price

7/24/14 Series A	4,288,500	$ 2.45	$0.75
7/24/14 Series B	4,795,321	$ 2.45	$0.75

The Company recognizes such warrants as liabilities at the fair value on each reporting date. The Company measured the fair value of these warrants as of December 31, 2015, and recorded other income of $1,814 resulting from the decrease of the liability associated with the fair value of the warrants for the year ended December 31, 2015. The Company measured the fair value of these warrants as of December 31, 2014, and recorded other income of $8,103 resulting from the decrease of the liability associated with the fair value of the warrants for the year ended December 31, 2014. The Company computed the value of the warrants using the binomial method. A summary of quantitative information with respect to the valuation methodology and significant unobservable inputs used for the Company's warrant liabilities that are categorized within Level 3 of the fair value hierarchy as of December 31, 2015, September 30, 2015 and December 31, 2014 is as follows:

	December 31, 2015			September 30, 2015			December 31, 2014

Stock price	$	1.11		$	1.14		$	1.20
Volatility		35.90 – 50.00	%		90.00	%		72.90 – 88.10	%
Risk-free interest rate		0.02% – 1.63	%		0.02% - 1.30	%		1.65	%
Expected dividend yield		0	%		0	%		0	%
Expected warrant life	.07 – 4.48 years			0.32 – 4.73 years			4.10 – 4.33 years

Recurring Level 3 Activity and Reconciliation

The table below provides a reconciliation of the beginning and ending balances for the liability measured at fair value using significant unobservable inputs (Level 3). The table reflects gains and losses for the year for all financial liabilities categorized as Level 3 as of December 31, 2015.

Fair Value Measurements Using Significant Unobservable Inputs (Level 3):

Issuance Date	January 1, 2015		Initial Measurements		Reclassed from Equity		Increase (Decrease) in Fair Value			December 31, 2015

10/31/2013	$	233	$	-	$	-	$	146		$	379
2/5/2014		266		-		-		449			715
7/24/2014 Series A		-		-		3,452		(1,037	)		2,415
7/24/2014 Series B		-		-		1,947		(221	)		1,726
6/22/2015		-		2,958		-		(1,151	)		1,807

Total	$	499	$	2,958	$	5,399	$	(1,814	)	$	7,042

During December 2015 the Company changed its method of calculating expected volatility that is used in its fair value measurements and measurements of share based compensation cost. The new method estimates expected volatility by using a combination of the Company's historical volatility since June 22, 2015, the acquisition date of the XTRAC and VTRAC businesses, plus the historical volatility of stocks of similar publicly-traded companies for a period matching the expected term of the underlying instrument. The Company believes that this method provides for a better estimate of future volatility because of the significant change to the overall Company resulting from the acquisition of the XTRAC and VTRAC businesses on June 22, 2015. The Company had historically calculated expected volatility based solely upon the historical volatility of the Company's daily closing stock price. Had the Company utilized the historical method of calculating volatility, the resulting volatility would have been 90% and the fair value of these warrants would have been $8,975 at December 31, 2015.

Stockholders' Equity

12 Months Ended

Dec. 31, 2015

Stockholders' Equity [Abstract]

Stockholders' Equity

Note 14

Stockholders' Equity:

Preferred Stock

The Company is authorized to issue 10,000,000 shares of preferred stock with a par value of $0.10 per share with such designation, rights and preferences as may be determined from time to time by the Company's Board of Directors. There were 6,505 shares and 11,787 shares of Series B convertible preferred stock issued and outstanding on December 31, 2015 and 2014, respectively.

On February 5, 2014, pursuant to a securities purchase agreement, dated as of January 31, 2014, the Company sold an aggregate of 12,300 shares of Series A convertible preferred stock, par value $0.10 and a stated value of $1,000 per share convertible into 1,464,287 shares of common stock at an initial conversion price of $8.40, and warrants to purchase up to 1,329,731 shares of common stock for net proceeds of $11,458. The warrants have an exercise price of $7.40 per share, are immediately exercisable and have a term of five years. These warrants have non-standard terms as they relate to a fundamental transaction and require a net-cash settlement upon a change in control of the Company and therefore are classified as a derivative liability and recorded at fair value on the inception date of February 5, 2014 and at each subsequent balance sheet date.

In connection with this financing, the Company also granted resale registration rights with respect to the shares of common stock underlying the Series A preferred stock and the warrants pursuant to the terms of a Registration Rights Agreement. The purchasers were entitled to receive liquidated damages upon the occurrence of a number of events relating to filing, effectiveness and maintaining an effective registration statement covering the shares underlying the Series A Preferred Stock and the warrants. The Company was unable to meet certain filing and effectiveness requirements and as a result paid liquidated damages to the Purchasers in the aggregate amount of $3,420 during the year ended December 31, 2014. Under the terms of the Registration Rights Agreement, the Company filed a registration statement on March 18, 2014, which was declared effective by the SEC on April 3, 2014.

On July 24, 2014, in connection with the July 2014 Debentures (see Note 10, Convertible Debentures), the Company exchanged 12,300 shares of Series A convertible preferred stock issued on February 5, 2014 with 12,300 shares of Series B convertible preferred stock at a stated value of $1,000 per share convertible into common stock at an initial price of $2.565 per share. The preferred stock is immediately convertible into an aggregate of 4,795,321 shares of common stock. Holders of the Series B convertible preferred stock are entitled to dividends only in the event that dividends are paid on the common stock, and the preferred stock has no preferences over the common stock. In connection with the exchange, the Company issued the July 2014 Series B warrants to purchase up to an aggregate of 4,795,321 shares of common stock at an exercise price of $2.45 per share, expiring in January 2016. The July 2014 Series B warrants are immediately exercisable and are subject to certain ownership limitations.

The $12,300 preferred stock value was allocated first to the fair value of the July 2014 Series B warrants, which totaled $2,487, then to the intrinsic value of the beneficial conversion feature of $1,887. The amount of the beneficial conversion feature was considered to be a deemed dividend on the date of issuance to the Series B preferred stockholders. Pursuant to the terms of the Purchase Agreement, the Series A convertible preferred stock was redeemed from the proceeds of the Series B convertible preferred stock. In September 2014, the Company amended the registration statement related to the Series A preferred stock to deregister those shares that would have been issuable upon conversion of the Series A preferred stock had it not already been redeemed by the proceeds of the Series B preferred stock.

During year ending December 31, 2015, 5,282.5 shares of Series B preferred stock were converted into 2,059,455 shares of common stock.

Common Stock and Warrants

The Company is authorized to issue 150,000,000 shares of common stock with a par value of $0.001 per share. There were 10,283,393 and 6,037,232 issued and outstanding at December 31, 2015 and 2014, respectively.

On October 29, 2013, the Company entered into a securities purchase agreement with certain accredited investors in connection with a $6,000,000 registered offering of 422,819 shares of the Company's common stock, fully paid prefunded warrants (the "October 2013 Series B Warrants") to purchase up to 434,325 shares of its common stock and additional warrants ("October 2013 Series A Warrants") to purchase up to 685,715 shares of its common stock. The October 2013 Series A Warrants are exercisable beginning on May 1, 2014 at a price of $8.50 per share and expire on May 1, 2019. The October 2013 Series B Warrants were exercisable immediately for no additional consideration. The offering closed on October 31, 2013. The holders exercised all of the October 2013 Series B Warrants in March 2014.

The October 2013 Series A Warrants have non-standard terms as they relate to a fundamental transaction and require a net-cash settlement upon a change in control of the Company and therefore are classified as a derivative. Therefore, these warrants have been recorded at fair value at the inception date of October 31, 2013, and will be recorded at their respective fair values at each subsequent balance sheet date.

Outstanding common stock warrants consist of the following:

Issue Date	Expiration Date	Total Warrants		Exercise Price

4/26/2013	4/26/2018		69,321	$	11.18
10/31/2013	4/30/2019		685,715	$	0.75
2/5/2014	2/5/2019		1,329,731	$	0.75
7/24/2014	7/24/2019		6,198,832	$	0.75 - $ 2.45
7/24/2014	1/24/2016		4,795,321	$	0.75
6/22/2015	6/22/2020		3,000,000	$	0.75
12/30/2015	12/30/2020		650,442	$	1.13
			16,729,362

- Definition

The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08.(d),(e))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21484-112644

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 310
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SAB TOPIC 4.E)
-URI http://asc.fasb.org/extlink&oid=27010918&loc=d3e74512-122707

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21488-112644

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.29-31)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 4
-Subparagraph (SAB TOPIC 4.C)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187143-122770

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21506-112644

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 30
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6405834&loc=d3e23285-112656

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21475-112644

Reference 11: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Preferred Stock
-URI http://asc.fasb.org/extlink&oid=6521494

Reference 12: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644

Reference 13: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21564-112644

Reference 14: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Staff Accounting Bulletin (SAB)
-Number Topic 4
-Section E

Reference 15: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Staff Accounting Bulletin (SAB)
-Number Topic 4
-Section C

+ Details

Stock-based compensation

12 Months Ended

Dec. 31, 2015

Stock-based compensation [Abstract]

Stock-based compensation

Note 15

Stock-based compensation:

Stock Options

On April 25, 2013, the Company's stockholders approved the Company's adoption of the new 2013 Stock Incentive Plan ("2013 Plan") having 3,500,000 shares available for issuance in respect of awards made thereunder. On September 30, 2015, the Company's stockholders approved an increase in the shares available for issuance from 3,500,000 to 13,250,000. The Company terminated the 2005 Stock Incentive Plan in December 2014. As of December 31, 2015, the aggregate number of shares of common stock remaining available for issuance for awards under the 2013 Plan totaled 10,565,648.

A summary of option transactions for all of the Company's stock options during the years ended December 31, 2015 and 2014 follows:

	Number of Stock Options			Weighted Average Exercise Price
Outstanding at December 31, 2013		306,616		$	16.20
Granted		1,205,162			1.70
Exercised		-			-
Expired/cancelled		(202,943	)		16.74
Outstanding at December 31, 2014		1,308,835			2.76
Granted		1,487,500			1.15
Exercised		-			-
Expired/cancelled		(111,983	)		10.70
Outstanding at December 31, 2015		2,684,352		$	1.54
Exercisable at December 31, 2015		1,729,177		$	1.66
Options expected to vest at December 31, 2015		952,850		$	1.26

The outstanding and exercisable options at December 31, 2015, have a range of exercise prices and associated weighted remaining contractual life and weighted average exercise price, as follows:

Options Range of Exercise Prices	Outstanding Number of Shares	Weighted Average Remaining Contractual Life (years)	Weighted Average Exercise Price	Exercisable Number of Shares	Exercisable Weighted Avg. Exercise Price
$0 - $1.25	1,487,500	9.80	$ 1.15	1,037,500	$ 1.14
$1.26 - $5.00	1,125,000	8.95	1.40	625,000	1.47
$5.01 - $10.00	53,402	7.92	6.75	50,352	6.74
$10.01 - $63.00	18,450	6.62	25.95	16,325	26.54
Total	2,684,352	9.38	$ 1.54	1,729,177	$ 1.66

As the share price as of December 31, 2015 was $1.11, the aggregate intrinsic value for options outstanding and exercisable was immaterial.

Stock awards under the Company's stock option plans have been granted with exercise prices that are no less than the market value of the stock on the date of the grant. Options granted under the plans are generally time-based or performance-based options and vesting varies accordingly. Options under the plans expire up to a maximum of ten years from the date of grant.

The fair value of each option award granted during the period is estimated on the date of grant using the Black-Scholes option valuation model and assumptions as noted in the following table:

	Years Ended December 31,
	2015	2014
Risk-free interest rate	1.80 - 1.90%	2.14 – 2.45%
Volatility	50.00 - 85.68%	75.51 – 73.87%
Expected dividend yield	0%	0%
Expected life	6.5 years	6.5 years
Estimated forfeiture rate	0%	0%

The expected life of the options is based on the observed and expected time to full-vesting, forfeiture and exercise. Groups of employees that have similar historical exercise behavior are considered separately for valuation purposes. The expected volatility assumptions were determined based upon the historical volatility of the Company's daily closing stock price. The risk-free rate is based on rates provided by the U.S. Treasury with a term equal to the expected life of the option. The Company has never paid dividends and does not currently anticipate paying any in the foreseeable future.

On December 15, 2015, the Company issued 100,000 shares of restricted stock to its Chief Executive Officer. The restricted shares have a purchase price of $0.01 per share and vest, and cease to be subject to the Company's right of repurchase, on January 5, 2016. The Company determined the fair value of the awards to be the fair value of the Company's common stock units on the date of issuance less the value paid for the award. The aggregate fair value of these restricted stock issued was $109.

On December 1, 2015, the Company granted an aggregate of 450,000 options to purchase common stock to the non-employee board directors with a strike price of $1.18. The options vest over a one year period and expire ten years from the date of grant. The aggregate fair value of the options granted was $253. During December 2015 the Company changed its method of calculating expected volatility that is used in its fair value measurements and measurements of share based compensation cost. The new method estimates expected volatility by using a combination of the Company's historical volatility since June 22, 2015, the acquisition date of the XTRAC and VTRAC businesses, plus the historical volatility of stocks of similar publicly-traded companies for a period matching the expected term of the underlying instrument. The Company believes that this method provides for a better estimate of future volatility because of the significant change to the overall Company resulting from the acquisition of the XTRAC and VTRAC businesses on June 22, 2015. The Company had historically calculated expected volatility based solely upon the historical volatility of the Company's daily closing stock price. Had the Company utilized the historical method of calculating volatility, the resulting volatility would have been 85.19% and the fair value of these warrants would have been $384 at December 31, 2015.

On September 30, 2015, the Company issued 37,500 to a new board director with a strike price of $1.14. The options vest on December 1, 2015 and expire ten years from the date of grant. The aggregate fair value of the options granted was $31.

On September 30, 2015, the Company granted an aggregate of 1,000,000 options to purchase common stock to two board directors, for their service on the finance committee of the Board of Directors, with a strike price of $1.14. The options vested immediately and expire ten years from the date of grant. The aggregate fair value of the options granted was $826.

Stock-based compensation expense, primarily included in general and administration, for the years ended December 31, 2015 and 2014 was $1,753 and $413, respectively. The year ended December 31, 2014, also included $20 of non-employee stock-based compensation. As of December 31, 2015 there was $635 in unrecognized compensation expense, which will be recognized over a weighted average period of 1.1 years.

Income Taxes

12 Months Ended

Dec. 31, 2015

Income Taxes [Abstract]

Income Taxes

Note 16

Income Taxes:

The Company accounts for income taxes using the asset and liability method for deferred income taxes.

The provision for income taxes includes federal, state and local income taxes currently payable and deferred taxes resulting from temporary differences between the financial statement and tax bases of assets and liabilities. Valuation allowances are recorded to reduce deferred tax assets when it is more likely than not that a tax benefit will not be realized.

The Company provides for income taxes offset by changes in valuation allowances.

The difference between the actual income tax benefit and that computed by applying the U.S. federal income tax rate of 34% to pretax loss from continuing operations is summarized below:

	For the Years Ended December 31,
	2015			2014

Computed expected tax benefit	$	(8,472	)	$	(4,270	)
State tax benefit, net of federal effect		(1,365	)		(217	)
Net increase in valuation allowance		9,956			4,487
Provision for income taxes	$	119		$	-

The tax effects of temporary differences that give rise to significant portions of the deferred tax assets and liabilities as of December 31, 2015 and 2014 are as follows:

	December 31,
	2015			2014

Deferred tax assets/(liabilities):
Net operating loss carryforward	$	64,075		$	57,367
Capitalized research and developmental costs		10,543			12,925
Inventory		47			689
Reserves & accrued expenses		3,295			135
Warrant liability		-			(3,123	)
Convertible debt discount		(11,182	)		-
Property & equipment		(355	)		(785	)
Non-cash compensation		1,054			3,840
Goodwill		(119	)		-
Total deferred tax assets		67,358			71,048
Less: valuation allowance		(67,477	)		(71,048	)
Net deferred tax assets/(liabilities)	$	(119	)	$	-

The ultimate realization of deferred tax assets is dependent upon the generation of future taxable income during the periods in which those temporary differences become deductible. Based on the Company's historical net losses, management does not believe that it is more-likely-than not that the Company will realize the benefits of these deferred tax assets and, accordingly, a full valuation allowance has been recorded against the deferred tax assets as of December 31, 2015 and 2014. The Company's valuation allowance against its deferred tax assets decreased by $3,571 for the year ended December 31, 2015 and increased by $4,487 for the year ended December 31, 2014.

At December 31, 2015 and 2014, the Company has federal net operating loss carryforwards of approximately $161,693 and $144,759, respectively, to offset future taxable income. The Company has experienced certain ownership changes which, under the provisions of Section 382 of the Internal Revenue Code of 1986, as amended, result in annual limitations on the Company's ability to utilize its net operating losses in the future. The February 2014, July 2014 and June 2015 equity raises by the Company, will likely limit the annual use of these net operating loss carryforwards.

FASB ASC 740 "Income Taxes" contains guidance with respect to uncertain tax positions which applies to all tax positions and clarifies the recognition of tax benefits in the financial statements by providing for a two-step approach of recognition and measurement. The first step involves assessing whether the tax position is more-likely-than-not to be sustained upon examination based upon its technical merits. The second step involves measurement of the amount to recognize. Tax positions that meet the more likely than not threshold are measured at the largest amount of tax benefit that is greater than 50% likely of being realized upon ultimate finalization with the taxing authority.

The Company does not have any unrecognized tax benefits or accrued penalties and interest. If such matters were to arise, the Company would recognize interest and penalties related to income tax matters in income tax expense. The earliest open tax year subject to examination is 2010.

Business Segments and Geographic Data

12 Months Ended

Dec. 31, 2015

Business Segments and Geographic Data [Abstract]

Business Segments and Geographic Data

Note 17

Business Segments and Geographic Data:

The Company organized its business into three operating segments to better align its organization based upon the Company's management structure, products and services offered, markets served and types of customers, as follows: The Dermatology Recurring Procedures segment derives its revenues from the XTRAC procedures performed by dermatologists. The Dermatology Procedures Equipment segment generates revenues from the sale of equipment, such as lasers and lamp products. The Dermatology Imaging segment generates revenues from the sale and usage of MelaFind devices. Management reviews financial information presented on an operating segment basis for the purposes of making certain operating decisions and assessing financial performance. On June 22, 2015, the Company acquired the XTRAC and VTRAC businesses and has classified the revenues and expenses of this business to the two Dermatology Procedures segments. Accordingly, these revenues and operating expenses are included only for the period of June 23, 2015 through December 31, 2015. There are no corresponding revenues for the year ended December 31, 2014.

Unallocated operating expenses include costs that are not specific to a particular segment but are general to the group; included are expenses incurred for administrative and accounting staff, general liability and other insurance, professional fees and other similar corporate expenses. Interest and other financing income (expense), net is also not allocated to the operating segments.

The following tables reflect results of operations from our business segments for the periods indicated below:

Year Ended December 31, 2015

	Dermatology Recurring Procedures			Dermatology Procedures Equipment			Dermatology Imaging			TOTAL
Revenues	$	14,616		$	3,591		$	288		$	18,495
Costs of revenues		4,680			1,989			7,050			13,719
Gross profit		9,936			1,602			(6,762	)		4,776
Gross profit %		68.0	%		44.6	%		(2347.8	%)		25.8	%

Allocated operating expenses:
Engineering and product development		676			104			1,249			2,029
Selling and marketing expenses		7,128			193			1,873			9,194

Unallocated operating expenses		-			-			-			10,028
		7,804			297			3,122			21,251
Income (loss) from operations		2,132			1,305			(9,884	)		(16,475	)

Interest expense, net		-			-			-			(10,200	)
Change in fair value of warrant liability		-			-			-			1,814
Other income (expense), net		-			-			-			33

Income (loss) before income taxes	$	2,132		$	1,305		$	(9,884	)	$	(24,828	)

Year Ended December 31, 2014

	Dermatology Recurring Procedures			Dermatology Procedures Equipment			Dermatology Imaging			TOTAL
Revenues	$	-		$	-		$	915		$	915
Costs of revenues		-			-			4,935			4,935
Gross profit		-			-			(4,020	)		(4,020	)
Gross profit %		0.0	%		0.0	%		(439.3	%)		(439.3	%)

Allocated operating expenses:
Engineering and product development		-			-			1,641			1,641
Selling and marketing expenses		-			-			3,140			3,140

Unallocated operating expenses		-			-			-			7,821
		-			-			4,781			12,602
Loss from operations		-			-			(8,801	)		(16,622	)

Interest expense, net		-			-			-			(2,372	)
Change in fair value of warrant liability		-			-			-			8,103
Gain on sale of assets		-			-			-			16
Other income (expense), net		-			-			-			150
Registration rights liquidated damages		-			-			-			(3,420	)

Loss before income taxes	$	-		$	-		$	(8,801	)	$	(14,145	)

For the year ended December 31, 2015 and 2014 there were no material net revenues attributable to any individual foreign country. Net revenues by geographic area were, as follows:

	Years Ended December 31,
	2015		2014
Domestic	$	14,724	$	340
Foreign		3,771		575
	$	18,495	$	915

As of December 31, 2015 and 2014, total assets by reportable segment were as follows:

	December 31,
Assets:	2015		2014
Dermatology Recurring Treatments	$	40,420	$	-
Dermatology Treatment Equipment		5,364		-
Dermatology Imaging		661		19,181
Other unallocated assets		4,927		889
Consolidated total	$	51,372	$	20,070

Long lived assets were 100% located in domestic markets for both of the years ended December 31, 2015 and 2014.

- Definition

The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 34
-URI http://asc.fasb.org/extlink&oid=51669610&loc=d3e8981-108599

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 41
-URI http://asc.fasb.org/extlink&oid=51669610&loc=d3e9038-108599

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 33
-URI http://asc.fasb.org/extlink&oid=51669610&loc=d3e8971-108599

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 12
-URI http://asc.fasb.org/extlink&oid=51669610&loc=d3e8595-108599

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=51669610&loc=d3e8380-108599

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-URI http://asc.fasb.org/extlink&oid=51669610&loc=d3e8933-108599

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 26
-URI http://asc.fasb.org/extlink&oid=51669610&loc=d3e8844-108599

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 35
-URI http://asc.fasb.org/extlink&oid=51669610&loc=d3e8984-108599

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 40
-URI http://asc.fasb.org/extlink&oid=51669610&loc=d3e9031-108599

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 42
-URI http://asc.fasb.org/extlink&oid=51669610&loc=d3e9054-108599

Reference 11: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 10
-URI http://asc.fasb.org/extlink&oid=51669610&loc=d3e8538-108599

Reference 12: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 29
-URI http://asc.fasb.org/extlink&oid=51669610&loc=d3e8864-108599

Reference 13: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 31
-URI http://asc.fasb.org/extlink&oid=51669610&loc=d3e8924-108599

Reference 14: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 30
-URI http://asc.fasb.org/extlink&oid=51669610&loc=d3e8906-108599

+ Details

Related Parties	12 Months Ended
Related Parties	Dec. 31, 2015
Related Parties [Abstract]
Related Parties	Note 18 Related Parties: On June 22, 2015, the Company entered into a securities purchase agreement with the Purchasers, including certain funds managed by Sabby Management, LLC and Broadfin Capital LLC, in connection with a private placement. We sold $10.0 million aggregate principal amount of Notes bearing interest at 9% per year, with a maturity date of the earlier of 30 days after the Company obtains stockholder approval of stock issuances under the Debentures and the Warrants or November 30, 2015. The Purchasers of the Notes were issued Warrants to purchase an aggregate of 3.0 million shares of common stock, having an exercise price of $0.75 per share. We also issued $32.5 million aggregate principal amount of Debentures that, subject to certain ownership limitations and stockholder approval conditions, will be convertible into 43,333,334 shares of common stock at an initial conversion price of $0.75 per share. The Debentures bear interest at the rate of 2.25% per year, and, unless previously converted, will mature on the five-year anniversary of the date of issuance. Our obligations under the Debt Securities are secured by a first priority lien on all of our assets, except for a second lien on our intellectual property. As a condition of the new term note facility (See Note 11, Long-term Debt below) the Debentures from both the 2014 and 2015 financings were amended. The Debentures holders' first priority lien was subordinated to the new term note facility. Additionally, as a condition of the term note facility, the maturity date of both Debentures was extended to June 30, 2021. Effective upon the date the Stockholder Approval, on September 30, 2015, the Company repriced outstanding Warrants held by certain investors to reduce the exercise price to $0.75 per share. In connection with this financing, the Company also granted to the Purchasers resale registration rights with respect to the shares of common stock underlying the Debentures and the Warrants pursuant to the terms of the Registration Rights Agreement. In addition to the registration rights, the Selling Stockholders are entitled to receive liquidated damages upon the occurrence of a number of events relating to filing, becoming effective and maintaining an effective registration statement covering the shares underlying the Debentures and the Warrants. The liquidated damages will be payable upon the occurrence of each of those events and each monthly anniversary thereof until cured. The amount of liquidated damages payable is equal to 2.0% of the aggregate purchase price paid by each Purchaser, provided, however, the maximum aggregate liquidated damages payable to a Purchaser shall be 12% of the aggregate subscription amount paid by such Purchaser pursuant to the Purchase Agreement. The liquidated damages shall accrue interest at a rate of 12% per annum (or such lesser maximum amount that is permitted to be paid by applicable law), accruing on a daily basis for each event until such event is cured. The Registration Rights Agreement requires the Company to file one or more registration statements for all of the securities that may be issued upon conversion of the Debentures and exercise of the Warrants issued to the Purchasers. Pursuant to the applicable transaction documents, however, certain Purchasers may not exercise their conversion/exercise rights for that number of shares of common stock which, together with all other shares owned by that Purchaser and its affiliates would result in more than 9.99% of our issued and outstanding shares of common stock calculated on the basis of the then outstanding shares. On November 4, 2015, the Company entered into consulting agreements with two of its directors, Jeffrey F. O'Donnell, Sr. and Samuel E. Navarro, the terms of which are the same. Under the terms of their respective agreements, each director agrees provide strategic support, advice and guidance to the Company and its management team in connection with the integration and operation of the expanded business, investor relations and internal and external business development activities. The consultant will make himself available to the Company's President and Chief Executive Officer and the management team on request at mutually convenient times and will report to the Board of Directors quarterly and otherwise when requested by the Board. The term of the agreement is from November 4, 2015 through June 30, 2016. The directors are each to be paid an up-front fee of $40,000 for advice and services rendered prior to the date of the agreement, a retainer of $10,000 per month, commencing November 10, 2015 and continuing on the tenth day of each month through June 10, 2016, and reimbursement of pre-approved, out-of-pocket expenses.

- Definition

The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.

+ References + Details

Significant Customer Concentration	12 Months Ended
Significant Customer Concentration	Dec. 31, 2015
Significant Customer Concentration [Abstract]
Significant Customer Concentration	Note 19 Significant Customer Concentration: For the year ended December 31, 2015, revenues from sales to the Company's international master distributor were $3,085, or 16.7%, of total revenues for such period. At December 31, 2015, the accounts receivable balance from GlobalMed Technologies was $533, or 13.1%, of total net accounts receivable. No other customer represented more than 10% of total company revenues for the years ended December 31, 2015 and 2014.

Subsequent Events	12 Months Ended
Subsequent Events	Dec. 31, 2015
Subsequent Events [Abstract]
Subsequent Events	Note 20 Subsequent Events: On January 22, 2016, the Company agreed to extend the expiration date of two outstanding Series B common stock warrants for six months. The two warrants, exercisable for an aggregate of 4,795,321 shares of Common Stock of the Company at an exercise price of $0.75 per share, may be exercised by the respective holder at any time until July 24, 2016. On January 29, 2016, the Company drew down the second tranche under the Credit Facility in the amount of $1.5 million. The Company has, therefore, drawn down the total amount of the $12.0 million available under the Credit Facility. In connection with the drawdown of the second tranche under the Credit Facility, the Company issued to the lenders warrants to purchase an aggregate of 99,057 shares of the Company's common stock at an exercise price of $1.06 per share, which equals the VWAP for the ten-day period prior to the January 29, 2016 closing date. The warrants are exercisable for five years from the date of issuance. The Warrants have not been registered under the Securities Act of 1933, as amended (the "Act"), pursuant to the exemption under Section 4(a)(2) of the Act. On February 24, 2016, investors converted debentures amounting to $15 into 20,000 shares of common stock. On March 3, 2016, investors converted debentures amounting to $38 into 50,000 shares of common stock. Additionally, on March 11, 2016, investors converted debentures amounting to $113 into 150,000 shares of common stock. See Note 10, Convertible Debentures.

The Company (Policies)

12 Months Ended

Dec. 31, 2015

The Company [Abstract]

Liquidity

Accounting Principles

The consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America ("US GAAP").

Principles of Consolidation

Reclassification

Use of Estimates

Revenue Recognition

Cash and Cash Equivalents

Accounts Receivable

Inventories

Property, Equipment and Depreciation

Patent Costs and Licensed Technologies

Other Intangible Assets

Accounting for the Impairment of Goodwill

Impairment of Long-Lived Assets and Intangibles

Functional Currency

Fair Value Measurements

	•	Level 1 – unadjusted quoted prices are available in active markets for identical assets or liabilities that the Company has the ability to access as of the measurement date.
	•	Level 2 – pricing inputs are other than quoted prices in active markets that are directly observable for the asset or liability or indirectly observable through corroboration with observable market data.

•

This hierarchy requires the Company to use observable market data, when available, and to minimize the use of unobservable inputs when determining fair value.

The Company's recurring fair value measurements at December 31, 2015 and 2014 are as follows:

	Fair Value as of December 31, 2015		Quoted Prices in Active Markets for Identical Assets (Level 1)		Significant other Observable Inputs (Level 2)		Significant Unobservable Inputs (Level 3)
Liabilities:
Warrant liability (Note 13)	$	7,042	$	-	$	-	$	7,042

	Fair Value as of December 31, 2014		Quoted Prices in Active Markets for Identical Assets (Level 1)		Significant other Observable Inputs (Level 2)		Significant Unobservable Inputs (Level 3)
Liabilities:
Warrant liability (Note 13)	$	499	$	-	$	-	$	499

Accrued Warranty Costs

	December 31, 2015

Accrual at beginning of year	$	48
Acquired in asset purchase		265
Additions charged to warranty expense		98
Expiring warranties/claimed satisfied		(185	)
Total		226
Less: current portion		(168	)
	$	58

Product Development Costs

Costs of research, new product development and product redesign are charged to expense as incurred in engineering and product development.

Advertising Costs

Advertising costs are charged to expenses as incurred. Advertising expenses amounted to approximately $2,500 and $0 for the years ended December 31, 2015 and 2014, respectively.

Income Taxes

Concentration of credit risks

Earnings Per Share

	December 31,
	2015	2014
Common stock equivalents of convertible debentures	46,435,127	5,228,465
Common stock purchase warrants	16,729,362	13,078,920
Common stock equivalents of convertible preferred stock	2,535,866	4,595,321
Common stock options	2,684,352	1,308,835
Total	68,384,707	24,211,541

Stock-Based Compensation

Adoption of New Accounting Standards

The adoption of ASU 2014-08 did not have a material impact on the Company's consolidated results of operations and financial condition.

Recently Issued Accounting Standards

In July, 2015, The FASB issued Accounting Standards Update No. 2015-11, Simplifying the Measurement of Inventory (Topic 330) ("ASU 2015-11").

The Company is in the process of assessing the impact, if any, of ASU 2015-11 on its consolidated financial statements.

In May 2014, The FASB issued Accounting Standards Update No. 2014-09, Revenue from Contracts with Customers (Topic 606) ("ASU 2014-09").

The Company (Tables)

12 Months Ended

Dec. 31, 2015

The Company [Abstract]

Fair Value Measurements on Recurring Basis

The Company's recurring fair value measurements at December 31, 2015 and 2014 are as follows:

	Fair Value as of December 31, 2015		Quoted Prices in Active Markets for Identical Assets (Level 1)		Significant other Observable Inputs (Level 2)		Significant Unobservable Inputs (Level 3)
Liabilities:
Warrant liability (Note 13)	$	7,042	$	-	$	-	$	7,042

	Fair Value as of December 31, 2014		Quoted Prices in Active Markets for Identical Assets (Level 1)		Significant other Observable Inputs (Level 2)		Significant Unobservable Inputs (Level 3)
Liabilities:
Warrant liability (Note 13)	$	499	$	-	$	-	$	499

Accrued Warranty Costs Activity

The activity in the warranty accrual during the year ended December 31, 2015 is summarized as follows:

	December 31, 2015

Accrual at beginning of year	$	48
Acquired in asset purchase		265
Additions charged to warranty expense		98
Expiring warranties/claimed satisfied		(185	)
Total		226
Less: current portion		(168	)
	$	58

Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share

Potential common stock equivalents outstanding as of December 31, 2015 and 2014 consist of common stock equivalents of common stock purchase warrants, senior secured convertible debentures, convertible preferred stock and common stock options, which are summarized as follows:

	December 31,
	2015	2014
Common stock equivalents of convertible debentures	46,435,127	5,228,465
Common stock purchase warrants	16,729,362	13,078,920
Common stock equivalents of convertible preferred stock	2,535,866	4,595,321
Common stock options	2,684,352	1,308,835
Total	68,384,707	24,211,541

Acquisition (Tables)

12 Months Ended

Dec. 31, 2015

Acquisition [Abstract]

Estimated Fair Value of Assets Acquired and Liabilities Assumed

The fair value of the Company's remaining fixed assets was estimated based on the cost approach which estimated the cost to replace.

Current assets	$	7,233
Property, plant and equipment		14,340
Identifiable intangible assets		16,100
Other assets		45
Total assets assumed		37,718

Current liabilities		(3,945	)
Note payable		(57	)
Other long term liabilities		(116	)
Total liabilities assumed		(4,118	)

Net assets acquired	$	33,600

Unaudited Pro-forma Results

The Company's unaudited pro-forma results for the year ended December 31, 2015 and 2014 summarize the combined results in the following table, assuming the asset purchase had occurred on January 1, 2014 and after giving effect to the acquisition adjustments, including amortization of the tangible and long-lived intangible assets acquired in the transaction:

	Year Ended December 31,
	2015			2014
	(unaudited)			(unaudited)

Net revenues	$	33,163		$	31,497
Net loss attributable to common shareholders	$	(34,252	)	$	(26,954	)
Net loss per basic and diluted share:	$	(4.01	)	$	(5.09	)
Shares used in calculating net loss per basic and diluted share:		8,536,699			5,295,929

Property and Equipment, net (Tables)

12 Months Ended

Dec. 31, 2015

Property and Equipment, net [Abstract]

Summary of Property and Equipment, Net

	December 31, 2015			December 31, 2014

Lasers placed-in-service	$	15,783		$	-
MelaFind systems		-			3,193
Equipment, computer hardware and software		1,219			1,084
Furniture and fixtures		2,080			1,969
Leasehold improvements		931			906
		20,012			7,152
Accumulated depreciation and amortization		(6,161	)		(5,191	)
Property and equipment, net	$	13,851		$	1,961

Patents and Licensed Technologies, net (Tables)

12 Months Ended

Dec. 31, 2015

Patents and Licensed Technologies, Net [Abstract]

Schedule of Patents and Licensed Technologies, Net

	December 31, 2015			December 31, 2014

Core technology	$	5,974		$	274

Product technology		2,000			-
		7,974			274
Accumulated amortization		(727	)		(237	)
Patents and licensed technologies, net	$	7,247		$	37

Estimated Amortization Expense for Amortizable Patents and Licensed Technologies Assets

Estimated amortization expense for amortizable patents and licensed technologies assets for the future periods is as follows:

2016	$	975
2017		975
2018		975
2019		975
2020		775
Thereafter		2,572
Total	$	7,247

Other Intangible Assets (Tables)

12 Months Ended

Dec. 31, 2015

Other Intangible Assets [Abstract]

Schedule of Other Definite-lived Intangible Assets

Set forth below is a detailed listing of other definite-lived intangible assets:

	December 31, 2015

Customer relationships	$	6,900
Tradenames		1,500
		8,400
Accumulated amortization		(420	)
Other intangible assets, net	$	7,980

Finite-lived Intangible Assets Amortization Expense

Estimated amortization expense for the above amortizable intangible assets for the future periods is as follows:

2016	$	840
2017		840
2018		840
2019		840
2020		840
Thereafter		3,780
Total	$	7,980

Warrants (Tables)

12 Months Ended

Dec. 31, 2015

Warrants [Abstract]

Schedule of Fair Value Hierarchy

The following is a listing of the warrants modified:

Issue date	# of warrants	Original Exercise Price	New Exercise Price

7/24/14 Series A	4,288,500	$ 2.45	$0.75
7/24/14 Series B	4,795,321	$ 2.45	$0.75

Warrants Fair Value Assumptions

A summary of quantitative information with respect to the valuation methodology and significant unobservable inputs used for the Company's warrant liabilities that are categorized within Level 3 of the fair value hierarchy as of December 31, 2015, September 30, 2015 and December 31, 2014 is as follows:

	December 31, 2015			September 30, 2015			December 31, 2014

Stock price	$	1.11		$	1.14		$	1.20
Volatility		35.90 – 50.00	%		90.00	%		72.90 – 88.10	%
Risk-free interest rate		0.02% – 1.63	%		0.02% - 1.30	%		1.65	%
Expected dividend yield		0	%		0	%		0	%
Expected warrant life	.07 – 4.48 years			0.32 – 4.73 years			4.10 – 4.33 years

Schedule of Derivative Warrant Liabilities

Fair Value Measurements Using Significant Unobservable Inputs (Level 3):

Issuance Date	January 1, 2015		Initial Measurements		Reclassed from Equity		Increase (Decrease) in Fair Value			December 31, 2015

10/31/2013	$	233	$	-	$	-	$	146		$	379
2/5/2014		266		-		-		449			715
7/24/2014 Series A		-		-		3,452		(1,037	)		2,415
7/24/2014 Series B		-		-		1,947		(221	)		1,726
6/22/2015		-		2,958		-		(1,151	)		1,807

Total	$	499	$	2,958	$	5,399	$	(1,814	)	$	7,042

Stockholders' Equity (Tables)

12 Months Ended

Dec. 31, 2015

Stockholders' Equity [Abstract]

Summary of Outstanding Common Stock Warrants

Outstanding common stock warrants consist of the following:

Issue Date	Expiration Date	Total Warrants		Exercise Price

4/26/2013	4/26/2018		69,321	$	11.18
10/31/2013	4/30/2019		685,715	$	0.75
2/5/2014	2/5/2019		1,329,731	$	0.75
7/24/2014	7/24/2019		6,198,832	$	0.75 - $ 2.45
7/24/2014	1/24/2016		4,795,321	$	0.75
6/22/2015	6/22/2020		3,000,000	$	0.75
12/30/2015	12/30/2020		650,442	$	1.13
			16,729,362

- Definition

Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.

+ References + Details

Stock-based compensation (Tables)

12 Months Ended

Dec. 31, 2015

Stock-based compensation [Abstract]

Schedule of Stock Option Plans

A summary of option transactions for all of the Company's stock options during the years ended December 31, 2015 and 2014 follows:

	Number of Stock Options			Weighted Average Exercise Price
Outstanding at December 31, 2013		306,616		$	16.20
Granted		1,205,162			1.70
Exercised		-			-
Expired/cancelled		(202,943	)		16.74
Outstanding at December 31, 2014		1,308,835			2.76
Granted		1,487,500			1.15
Exercised		-			-
Expired/cancelled		(111,983	)		10.70
Outstanding at December 31, 2015		2,684,352		$	1.54
Exercisable at December 31, 2015		1,729,177		$	1.66
Options expected to vest at December 31, 2015		952,850		$	1.26

Schedule of Stock Options Outstanding

The outstanding and exercisable options at December 31, 2015, have a range of exercise prices and associated weighted remaining contractual life and weighted average exercise price, as follows:

Options Range of Exercise Prices	Outstanding Number of Shares	Weighted Average Remaining Contractual Life (years)	Weighted Average Exercise Price	Exercisable Number of Shares	Exercisable Weighted Avg. Exercise Price
$0 - $1.25	1,487,500	9.80	$ 1.15	1,037,500	$ 1.14
$1.26 - $5.00	1,125,000	8.95	1.40	625,000	1.47
$5.01 - $10.00	53,402	7.92	6.75	50,352	6.74
$10.01 - $63.00	18,450	6.62	25.95	16,325	26.54
Total	2,684,352	9.38	$ 1.54	1,729,177	$ 1.66

Schedule of Fair Value of Each Option Award Granted

The fair value of each option award granted during the period is estimated on the date of grant using the Black-Scholes option valuation model and assumptions as noted in the following table:

	Years Ended December 31,
	2015	2014
Risk-free interest rate	1.80 - 1.90%	2.14 – 2.45%
Volatility	50.00 - 85.68%	75.51 – 73.87%
Expected dividend yield	0%	0%
Expected life	6.5 years	6.5 years
Estimated forfeiture rate	0%	0%

Income Taxes (Tables)

12 Months Ended

Dec. 31, 2015

Income Taxes [Abstract]

Computation of U.S. federal income tax rate to pretax loss from continuing operations

The difference between the actual income tax benefit and that computed by applying the U.S. federal income tax rate of 34% to pretax loss from continuing operations is summarized below:

	For the Years Ended December 31,
	2015			2014

Computed expected tax benefit	$	(8,472	)	$	(4,270	)
State tax benefit, net of federal effect		(1,365	)		(217	)
Net increase in valuation allowance		9,956			4,487
Provision for income taxes	$	119		$	-

Summary of deferred tax assets and liabilities

The tax effects of temporary differences that give rise to significant portions of the deferred tax assets and liabilities as of December 31, 2015 and 2014 are as follows:

	December 31,
	2015			2014

Deferred tax assets/(liabilities):
Net operating loss carryforward	$	64,075		$	57,367
Capitalized research and developmental costs		10,543			12,925
Inventory		47			689
Reserves & accrued expenses		3,295			135
Warrant liability		-			(3,123	)
Convertible debt discount		(11,182	)		-
Property & equipment		(355	)		(785	)
Non-cash compensation		1,054			3,840
Goodwill		(119	)		-
Total deferred tax assets		67,358			71,048
Less: valuation allowance		(67,477	)		(71,048	)
Net deferred tax assets/(liabilities)	$	(119	)	$	-

Business Segments and Geographic Data (Tables)

12 Months Ended

Dec. 31, 2015

Business Segments and Geographic Data [Abstract]

Schedule of Segment Reporting Information by Segment

The following tables reflect results of operations from our business segments for the periods indicated below:

Year Ended December 31, 2015

	Dermatology Recurring Procedures			Dermatology Procedures Equipment			Dermatology Imaging			TOTAL
Revenues	$	14,616		$	3,591		$	288		$	18,495
Costs of revenues		4,680			1,989			7,050			13,719
Gross profit		9,936			1,602			(6,762	)		4,776
Gross profit %		68.0	%		44.6	%		(2347.8	%)		25.8	%

Allocated operating expenses:
Engineering and product development		676			104			1,249			2,029
Selling and marketing expenses		7,128			193			1,873			9,194

Unallocated operating expenses		-			-			-			10,028
		7,804			297			3,122			21,251
Income (loss) from operations		2,132			1,305			(9,884	)		(16,475	)

Interest expense, net		-			-			-			(10,200	)
Change in fair value of warrant liability		-			-			-			1,814
Other income (expense), net		-			-			-			33

Income (loss) before income taxes	$	2,132		$	1,305		$	(9,884	)	$	(24,828	)

Year Ended December 31, 2014

	Dermatology Recurring Procedures			Dermatology Procedures Equipment			Dermatology Imaging			TOTAL
Revenues	$	-		$	-		$	915		$	915
Costs of revenues		-			-			4,935			4,935
Gross profit		-			-			(4,020	)		(4,020	)
Gross profit %		0.0	%		0.0	%		(439.3	%)		(439.3	%)

Allocated operating expenses:
Engineering and product development		-			-			1,641			1,641
Selling and marketing expenses		-			-			3,140			3,140

Unallocated operating expenses		-			-			-			7,821
		-			-			4,781			12,602
Loss from operations		-			-			(8,801	)		(16,622	)

Interest expense, net		-			-			-			(2,372	)
Change in fair value of warrant liability		-			-			-			8,103
Gain on sale of assets		-			-			-			16
Other income (expense), net		-			-			-			150
Registration rights liquidated damages		-			-			-			(3,420	)

Loss before income taxes	$	-		$	-		$	(8,801	)	$	(14,145	)

Schedule of Net Revenues by Geographic Areas

For the year ended December 31, 2015 and 2014 there were no material net revenues attributable to any individual foreign country. Net revenues by geographic area were, as follows:

	Years Ended December 31,
	2015		2014
Domestic	$	14,724	$	340
Foreign		3,771		575
	$	18,495	$	915

Summary of Total Assets by Reportable Segment

As of December 31, 2015 and 2014, total assets by reportable segment were as follows:

	December 31,
Assets:	2015		2014
Dermatology Recurring Treatments	$	40,420	$	-
Dermatology Treatment Equipment		5,364		-
Dermatology Imaging		661		19,181
Other unallocated assets		4,927		889
Consolidated total	$	51,372	$	20,070

The Company (Details) $ / shares in Units, $ in Thousands		3 Months Ended	12 Months Ended
The Company (Details) $ / shares in Units, $ in Thousands	Jun. 22, 2015 USD ($) $ / shares	Jun. 30, 2015 USD ($)	Dec. 31, 2015 USD ($) shares Systems Channel $ / shares	Dec. 31, 2014 USD ($) shares	Dec. 30, 2015 $ / shares
Business Acquisition [Line Items]
Exercise price of warrants (in dollars per share) \| $ / shares	$ 0.75		$ 0.75		$ 1.13
Liquidity [Abstract]
Accumulated deficit			$ (207,240)	$ (182,293)
Revenue Recognition [Abstract]
Number of distribution channels \| Channel			2
Accounts Receivable, Net [Abstract]
Allowance for doubtful accounts			$ 45	95
Inventories [Abstract]
Reserves on inventory			0	870
Inventory write-offs			$ 4,818	1,084
Property, Plant and Equipment [Line Items]
Property, plant and equipment, useful life			5 years
Write-down, property and equipment		$ 920	$ 920	0
Finite-Lived Intangible Assets [Line Items]
Impairment of intangible assets			0
Fair Value Assets And Liabilities, Measured On Recurring And Nonrecurring Basis [Line Items]
Warrant liability (Note 13)			7,042	499
Fair value of debt			15,958	5,001
Product Warranty Accrual [Roll Forward]
Accrual at beginning of year			48
Acquired in asset purchase			265
Additions charged to warranty expense			98
Expiring warranties/claimed satisfied			(185)
Total			226	48
Less: current portion			(168)
Accrued warranty, non-current portion			58
Advertising Costs [Abstract]
Advertising Expense			$ 2,500	$ 0
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Potential common stock equivalents (in shares) \| shares			68,384,707	24,211,541
Recently Issued Accounting Standards [Abstract]
Deferred financing costs reclassified against long-term debt			$ 328
Deferred financing costs reclassified against convertible debentures			$ 966
Minimum [Member]
Product Warranty Liability [Line Items]
Standard warranty period			1 year
Offered warranty period			3 years
Maximum [Member]
Product Warranty Liability [Line Items]
Standard warranty period			2 years
Offered warranty period			4 years
Quoted Prices in Active Markets for Identical Assets (Level 1) [Member]
Fair Value Assets And Liabilities, Measured On Recurring And Nonrecurring Basis [Line Items]
Warrant liability (Note 13)			$ 0	$ 0
Significant other Observable Inputs (Level 2) [Member]
Fair Value Assets And Liabilities, Measured On Recurring And Nonrecurring Basis [Line Items]
Warrant liability (Note 13)			0	0
Significant Unobservable Inputs (Level 3) [Member]
Fair Value Assets And Liabilities, Measured On Recurring And Nonrecurring Basis [Line Items]
Warrant liability (Note 13)			$ 7,042	$ 499
2015 Financing [Member]
Business Acquisition [Line Items]
Aggregate principal amount of debt	$ 42,500
Computer Hardware and Software [Member] \| Minimum [Member]
Property, Plant and Equipment [Line Items]
Property, plant and equipment, useful life			3 years
Computer Hardware and Software [Member] \| Maximum [Member]
Property, Plant and Equipment [Line Items]
Property, plant and equipment, useful life			7 years
Furniture and Fixtures [Member] \| Minimum [Member]
Property, Plant and Equipment [Line Items]
Property, plant and equipment, useful life			3 years
Furniture and Fixtures [Member] \| Maximum [Member]
Property, Plant and Equipment [Line Items]
Property, plant and equipment, useful life			7 years
Machinery and Equipment [Member] \| Minimum [Member]
Property, Plant and Equipment [Line Items]
Property, plant and equipment, useful life			3 years
Machinery and Equipment [Member] \| Maximum [Member]
Property, Plant and Equipment [Line Items]
Property, plant and equipment, useful life			7 years
Patents and Licensed Technologies [Member] \| Minimum [Member]
Finite-Lived Intangible Assets [Line Items]
Estimated useful life			8 years
Patents and Licensed Technologies [Member] \| Maximum [Member]
Finite-Lived Intangible Assets [Line Items]
Estimated useful life			12 years
Core Technology [Member]
Finite-Lived Intangible Assets [Line Items]
Estimated useful life			10 years
Product Technology [Member]
Finite-Lived Intangible Assets [Line Items]
Estimated useful life			5 years
Other Intangible Assets [Member]
Finite-Lived Intangible Assets [Line Items]
Estimated useful life			10 years
XTRAC and VTRAC [Member]
Business Acquisition [Line Items]
Acquisition price	$ 42,528
XTRAC and VTRAC [Member] \| 2015 Financing [Member]
Business Acquisition [Line Items]
Aggregate principal amount of debt			$ 10,000
Interest rate			9.00%
Warrants issued and outstanding to purchase common stock (in shares) \| shares			3,000,000
Exercise price of warrants (in dollars per share) \| $ / shares			$ 0.75
XTRAC and VTRAC [Member] \| Senior Secured Convertible Debentures [Member]
Business Acquisition [Line Items]
Aggregate principal amount of debt			$ 32,500
Shares issued on conversion of senior secured convertible debentures (in shares) \| shares			43,333,334
Initial conversion price (in dollars per share) \| $ / shares			$ 0.75
Interest rate			2.25%
Maturity period of debentures			5 years
Debentures secured by subordinated lien			$ 500
XTRAC and VTRAC [Member] \| Core Technology [Member]
Finite-Lived Intangible Assets [Line Items]
Estimated useful life			10 years
XTRAC and VTRAC [Member] \| Product Technology [Member]
Finite-Lived Intangible Assets [Line Items]
Estimated useful life			5 years
XTRAC [Member]
Business Acquisition [Line Items]
Number of systems placed in dermatologists offices \| Systems			718
Upfront charges			$ 0
Common Stock Equivalents of Convertible Debentures [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Potential common stock equivalents (in shares) \| shares			46,435,127	5,228,465
Common Stock Purchase Warrants [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Potential common stock equivalents (in shares) \| shares			16,729,362	13,078,920
Common Stock Equivalents of Convertible Preferred Stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Potential common stock equivalents (in shares) \| shares			2,535,866	4,595,321
Common Stock Options [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Potential common stock equivalents (in shares) \| shares			2,684,352	1,308,835

Acquisition (Details) - USD ($) $ / shares in Units, $ in Thousands		12 Months Ended
	Jun. 22, 2015	Dec. 31, 2015	Dec. 31, 2014
Aggregate Fair Value of Assets Acquired and the Liabilities Assumed [Abstract]
Goodwill		$ 8,928	$ 0
Product Technology [Member]
Business Acquisition [Line Items]
Estimated useful life		5 years
Core Technology [Member]
Business Acquisition [Line Items]
Estimated useful life		10 years
Trade Names [Member]
Business Acquisition [Line Items]
Estimated useful life		10 years
Customer Relationships [Member]
Business Acquisition [Line Items]
Estimated useful life		10 years
XTRAC and VTRAC [Member]
Business Acquisition [Line Items]
Acquisition price	$ 42,528
Aggregate Fair Value of Assets Acquired and the Liabilities Assumed [Abstract]
Current assets	7,233
Property, plant and equipment	14,340
Identifiable intangible assets	16,100
Other assets	45
Total assets assumed	37,718
Current liabilities	(3,945)
Note payable	(57)
Other long term liabilities	(116)
Total liabilities assumed	(4,118)
Net assets acquired	$ 33,600
Goodwill		$ 8,928
Unaudited Pro-forma Results [Abstract]
Net revenues		33,163	31,497
Net loss attributable to common shareholders		$ (34,252)	$ (26,954)
Net loss per basic and diluted share: (in dollars per share)		$ (4.01)	$ (5.09)
Shares used in calculating net loss per basic and diluted share: (in shares)		8,536,699	5,295,929
XTRAC and VTRAC [Member] \| Product Technology [Member]
Business Acquisition [Line Items]
Estimated useful life		5 years
XTRAC and VTRAC [Member] \| Core Technology [Member]
Business Acquisition [Line Items]
Estimated useful life		10 years
XTRAC and VTRAC [Member] \| Trade Names [Member]
Business Acquisition [Line Items]
Estimated useful life		10 years
XTRAC and VTRAC [Member] \| Customer Relationships [Member]
Business Acquisition [Line Items]
Estimated useful life		10 years

Inventories (Details) - USD ($) $ in Thousands	12 Months Ended
Inventories (Details) - USD ($) $ in Thousands	Dec. 31, 2015	Dec. 31, 2014
Schedule of inventory [Abstract]
Raw materials and work in progress	$ 3,706	$ 2,553
Finished goods	422	4,131
Total inventories	4,128	6,684
Reserve for obsolete inventory	0	(870)
Reserve for inventory repairs	0	(539)
Inventories, net	4,128	5,275
Inventory [Line Items]
Excess and obsolete inventories write off	4,818	$ 1,084
MelaFind Systems [Member]
Inventory [Line Items]
Excess and obsolete inventories write off	$ 5,688

Property and Equipment, net (Details) - USD ($) $ in Thousands	3 Months Ended	12 Months Ended
	Jun. 30, 2015	Dec. 31, 2015	Dec. 31, 2014
Property, Plant and Equipment [Line Items]
Property and equipment, gross		$ 20,012	$ 7,152
Accumulated depreciation and amortization		(6,161)	(5,191)
Property and equipment, net		13,851	1,961
Depreciation and related amortization expense		3,141	1,785
Impairment of long-lived assets	$ 920	920	0
Lasers Placed-In-Service [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, gross		15,783	0
MELAFind Systems [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, gross		0	3,193
Equipment, Computer Hardware and Software [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, gross		1,219	1,084
Furniture and Fixtures [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, gross		2,080	1,969
Leasehold Improvements [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, gross		$ 931	$ 906

Patents and Licensed Technologies, net (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014
Finite-Lived Intangible Assets [Line Items]
Patents and licensed technologies, net	$ 7,247	$ 37
Estimated amortization expense [Abstract]
Patents and licensed technologies, net	7,247	37
Core Technology [Member]
Finite-Lived Intangible Assets [Line Items]
Patents and licensed technologies, gross	$ 5,974	274
Estimated useful life	10 years
Core Technology [Member] \| XTRAC and VTRAC [Member]
Finite-Lived Intangible Assets [Line Items]
Patents and licensed technologies, net	$ 5,700
Estimated useful life	10 years
Estimated amortization expense [Abstract]
Patents and licensed technologies, net	$ 5,700
Product Technology [Member]
Finite-Lived Intangible Assets [Line Items]
Patents and licensed technologies, gross	$ 2,000	0
Estimated useful life	5 years
Product Technology [Member] \| XTRAC and VTRAC [Member]
Finite-Lived Intangible Assets [Line Items]
Patents and licensed technologies, net	$ 2,000
Estimated useful life	5 years
Estimated amortization expense [Abstract]
Patents and licensed technologies, net	$ 2,000
Patents and Licensed Technologies [Member]
Finite-Lived Intangible Assets [Line Items]
Patents and licensed technologies, gross	7,974	274
Accumulated amortization	(727)	(237)
Patents and licensed technologies, net	7,247	37
Amortization expense	490	5
Estimated amortization expense [Abstract]
2016	975
2017	975
2018	975
2019	975
2020	775
Thereafter	2,572
Patents and licensed technologies, net	$ 7,247	$ 37

Goodwill (Details) $ in Thousands	12 Months Ended
Goodwill (Details) $ in Thousands	Dec. 31, 2015 USD ($)
Goodwill [Roll Forward]
Balance at beginning of period	$ 0
Additions for the asset purchase	8,928
Balance at end of period	8,928
Accumulated impairment losses of goodwill	$ 0

Other Intangible Assets (Details) - USD ($) $ in Thousands	12 Months Ended
Other Intangible Assets (Details) - USD ($) $ in Thousands	Dec. 31, 2015	Dec. 31, 2014
Finite-Lived Intangible Assets [Line Items]
Other intangible assets, net	$ 7,980	$ 0
Estimated amortization expense [Abstract]
Other intangible assets, net	7,980	0
Customer Relationships [Member]
Finite-Lived Intangible Assets [Line Items]
Other intangible assets, gross	$ 6,900
Estimated useful life	10 years
Tradenames [Member]
Finite-Lived Intangible Assets [Line Items]
Other intangible assets, gross	$ 1,500
Estimated useful life	10 years
Customer Relationships and Tradenames [Member]
Finite-Lived Intangible Assets [Line Items]
Other intangible assets, gross	$ 8,400
Accumulated amortization	(420)
Other intangible assets, net	7,980
Amortization expense of other intangible assets	420	$ 0
Estimated amortization expense [Abstract]
2016	840
2017	840
2018	840
2019	840
2020	840
Thereafter	3,780
Other intangible assets, net	$ 7,980

Other Accrued Liabilities (Details) - USD ($) $ in Thousands	Dec. 31, 2015	Dec. 31, 2014
Other Accrued Liabilities [Abstract]
Accrued warranty, current, see Note 1	$ 168
Accrued compensation, including commissions and vacation	1,336	$ 192
Accrued sales and other taxes	349	105
Accrued professional fees	265	98
Vendor settlement	0	282
Other accrued liabilities	43	234
Total other accrued liabilities	$ 2,161	$ 959

Senior Notes Payable (Details) - USD ($) $ / shares in Units, $ in Thousands			12 Months Ended
	Dec. 30, 2015	Jun. 22, 2015	Dec. 31, 2015	Dec. 31, 2014
Debt Instrument [Line Items]
Debt discount fully amortized			$ 8,479	$ 1,943
Assumptions used to value the warrants [Abstract]
Number of shares underlying warrants (in shares)	650,442	3,000,000	3,000,000
Exercise price (in dollars per share)	$ 1.13	$ 0.75	$ 0.75
Share price (in dollars per share)	$ 1.11	$ 1.38	$ 1.11
Fair value of warrants	$ 321,045	$ 2,959	$ 1,807
Probability of stockholder approval		80.00%	100.00%
Volatility	50.00%	90.00%	50.00%
Risk-free interest rate	1.80%	1.62%	1.65%
Expected dividend yield	0.00%	0.00%	0.00%
Expected warrant life	5 years	5 years	4 years 5 months 23 days
Financing 2015 [Member]
Debt Instrument [Line Items]
Aggregate principal amount of debt		$ 42,500
Senior Secured Notes Payable [Member]
Debt Instrument [Line Items]
Aggregate principal amount of debt		$ 10,000
Number of days for stockholders approval considered for maturity date		30 days	30 days
Interest rate			9.00%
Warrants liability repayment terms			5 months
Debt discount fully amortized			$ 2,958
Senior Secured Notes Payable [Member] \| Financing 2015 [Member]
Debt Instrument [Line Items]
Aggregate principal amount of debt		$ 10,000
Number of days for stockholders approval considered for maturity date		30 days
Interest rate		9.00%
Debentures [Member] \| Financing 2015 [Member]
Debt Instrument [Line Items]
Senior secured convertible debentures		$ 500

Convertible Debentures (Details) $ / shares in Units, $ in Thousands			12 Months Ended
	Jun. 22, 2015 USD ($) shares $ / shares	Jul. 21, 2014 USD ($) shares $ / shares	Dec. 31, 2015 USD ($) shares $ / shares	Dec. 30, 2015 USD ($) $ / shares	Dec. 31, 2014 USD ($) $ / shares	Jul. 24, 2014 $ / shares	Oct. 29, 2013 $ / shares shares
Debt Instrument [Line Items]
Total convertible debt			$ 10,804		$ 5,001
Exercise price of warrants (in dollars per share) \| $ / shares	$ 0.75		$ 0.75	$ 1.13
Common stock, par value (in dollars per share) \| $ / shares			$ 0.001		$ 0.001
Fair value of warrants	$ 2,959		$ 1,807	$ 321,045
Interest expense on debt			3,601
Debentures outstanding amount			$ 40,993
Extended maturity date of Debenture			June 30, 2021
Maximum [Member]
Debt Instrument [Line Items]
Discounted cash flow change			10.00%
Series A Warrants [Member]
Debt Instrument [Line Items]
Number of warrants to purchase common stock (in shares) \| shares		6,198,832	6,198,832				685,715
Exercise price of warrants (in dollars per share) \| $ / shares		$ 2.45	$ 0.75			$ 2.45	$ 8.50
Warrants expiration date			Jul. 01, 2019
Common stock, par value (in dollars per share) \| $ / shares		$ 0.001
Senior Secured 2.25% Convertible Debentures [Member]
Debt Instrument [Line Items]
Total convertible debt			$ 6,011		$ 0
Debt instrument, unamortized discount			$ 26,267
Interest rate			2.25%
Aggregate principal amount of debt	$ 32,500		$ 32,500
Number of shares debt convertible (in shares) \| shares	43,333,334		43,333,334
Initial conversion price (in dollars per share) \| $ / shares	$ 0.75		$ 0.75
Debt instrument, maturity period	5 years		5 years
Maturity date			Jun. 22, 2020
Debt instrument, convertible, beneficial conversion feature			$ 27,300
Senior Secured 2.25% Convertible Debentures [Member] \| Maximum [Member]
Debt Instrument [Line Items]
Initial conversion price (in dollars per share) \| $ / shares			$ 1.38
Senior Secured 2.25% Convertible Debentures [Member] \| Minimum [Member]
Debt Instrument [Line Items]
Initial conversion price (in dollars per share) \| $ / shares			$ 0.75
Senior Secured 4% Convertible Debentures [Member]
Debt Instrument [Line Items]
Total convertible debt			$ 4,793		5,001
Debt instrument, unamortized discount		$ 10,353	$ 3,922		$ 8,410
Interest rate			4.00%
Aggregate principal amount of debt		$ 15,000
Number of shares debt convertible (in shares) \| shares		5,847,955	5,847,955
Initial conversion price (in dollars per share) \| $ / shares		$ 2.565	$ 2.565
Debt instrument, maturity period			5 years
Maturity date			Jul. 01, 2019
Debt instrument, convertible, beneficial conversion feature		$ 4,565
Fair value of warrants		5,296
Fair value of warrants adjustment (income) expense		491
Debt instrument initial carrying amount		$ 4,647
July 2014 Note [Member]
Debt Instrument [Line Items]
Debentures converted in shares of common stock, value			$ 4,593
Debt conversion, converted instrument, issued (in shares) \| shares			1,790,671
June 2015 Note [Member]
Debt Instrument [Line Items]
Debentures converted in shares of common stock, value			$ 222
Debt conversion, converted instrument, issued (in shares) \| shares			296,035

Long-term Debt (Details) $ / shares in Units, $ in Thousands				12 Months Ended
	Jan. 29, 2016 USD ($)	Dec. 30, 2015 USD ($) Tranche $ / shares shares	Jun. 22, 2015 USD ($) $ / shares shares	Dec. 31, 2015 USD ($) $ / shares shares	Dec. 31, 2014 USD ($)	Jan. 22, 2016 Tranche
Line of Credit Facility [Line Items]
Repayment of debt				$ 10,000	$ 0
Outstanding long term debt				$ 10,179	$ 0
Assumptions used to value the warrants [Abstract]
Number of shares underlying warrants (in shares) \| shares		650,442	3,000,000	3,000,000
Exercise price (in dollars per share) \| $ / shares		$ 1.13	$ 0.75	$ 0.75
Share price (in dollars per share) \| $ / shares		$ 1.11	$ 1.38	$ 1.11
Fair value of warrants		$ 321,045	$ 2,959	$ 1,807
Probability of stockholder approval			80.00%	100.00%
Volatility		50.00%	90.00%	50.00%
Risk-free interest rate		1.80%	1.62%	1.65%
Expected dividend yield		0.00%	0.00%	0.00%
Expected warrant life		5 years	5 years	4 years 5 months 23 days
Expected volatility rate if historical method used				77.00%
Fair value of warrants if historical method used				$ 439
Subsequent Event [Member]
Line of Credit Facility [Line Items]
Number of tranches \| Tranche						2
MidCap Financial Trust [Member]
Line of Credit Facility [Line Items]
Outstanding long term debt				$ 10,179
Repayment term				60 days
MidCap Financial Trust [Member] \| Term-Note Credit Facility [Member]
Line of Credit Facility [Line Items]
Maximum borrowing capacity under the agreement		$ 12,000
Number of tranches \| Tranche		2
MidCap Financial Trust [Member] \| Term-Note Credit Facility [Member] \| First Tranche [Member]
Line of Credit Facility [Line Items]
Proceeds from credit facility		$ 10,500
Repayment of debt		$ (10,000)
MidCap Financial Trust [Member] \| Term-Note Credit Facility [Member] \| Second Tranche [Member] \| Subsequent Event [Member]
Line of Credit Facility [Line Items]
Proceeds from credit facility	$ 1,500

Commitments and Contingencies (Details) $ in Thousands	12 Months Ended
Commitments and Contingencies (Details) $ in Thousands	Dec. 31, 2015 USD ($) Lease	Dec. 31, 2014 USD ($)
Commitments and Contingencies [Abstract]
Number of operating leases \| Lease	3
Rent expense charged to operations	$ 748	$ 445
Future Annual Minimum Payments under Operating Leases [Abstract]
2016	861
2017	205
Thereafter	19
Total	$ 1,085

Warrants (Details) $ / shares in Units, $ in Thousands			9 Months Ended	12 Months Ended
Warrants (Details) $ / shares in Units, $ in Thousands	Dec. 30, 2015 USD ($) $ / shares	Jun. 22, 2015 USD ($) $ / shares	Sep. 30, 2015 USD ($) $ / shares	Dec. 31, 2015 USD ($) shares $ / shares	Dec. 31, 2014 USD ($) $ / shares	Jul. 24, 2014 $ / shares	Jul. 21, 2014 $ / shares shares	Oct. 29, 2013 $ / shares shares
Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques [Line Items]
Fair value of warrants	$ 321,045	$ 2,959		$ 1,807
Deemed dividend				$ 2,962	$ 1,887
Warrants Modified [Abstract]
Exercise price of warrants (in dollars per share) \| $ / shares	$ 1.13	$ 0.75		$ 0.75
Expected volatility rate if historical method used				77.00%
Fair value of warrants if historical method used				$ 439
Fair Value Assumptions [Abstract]
Stock price (in dollars per share) \| $ / shares	$ 1.11	$ 1.38		$ 1.11
Volatility	50.00%	90.00%		50.00%
Risk-free interest rate	1.80%	1.62%		1.65%
Expected dividend yield	0.00%	0.00%		0.00%
Expected warrant life	5 years	5 years		4 years 5 months 23 days
7/24/2014 Series A [Member]
Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques [Line Items]
Warrants issued to purchase common stock (in shares) \| shares				6,198,832			6,198,832	685,715
Warrants Modified [Abstract]
Number of warrants \| shares				4,288,500
Exercise price of warrants (in dollars per share) \| $ / shares				$ 0.75		$ 2.45	$ 2.45	$ 8.50
7/24/2014 Series B [Member]
Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques [Line Items]
Warrants issued to purchase common stock (in shares) \| shares								434,325
Warrants Modified [Abstract]
Number of warrants \| shares				4,795,321
Exercise price of warrants (in dollars per share) \| $ / shares				$ 0.75		$ 2.45
Warrant [Member]
Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques [Line Items]
Warrants issued to purchase common stock (in shares) \| shares				3,000,000
Debentures in excess held by the investors			$ 5,000
Deemed dividend			$ 2,962
Warrants Modified [Abstract]
Exercise price of warrants (in dollars per share) \| $ / shares			$ 0.75
Fair value of warrants adjustment (income) expense				$ (1,814)	$ (8,103)
Expected volatility rate if historical method used				90.00%
Fair value of warrants if historical method used				$ 8,975
Fair Value Assumptions [Abstract]
Stock price (in dollars per share) \| $ / shares			$ 1.14	$ 1.11	$ 1.20
Volatility			90.00%
Risk-free interest rate					1.65%
Expected dividend yield			0.00%	0.00%	0.00%
Warrant [Member] \| Minimum [Member]
Fair Value Assumptions [Abstract]
Volatility				35.90%	72.90%
Risk-free interest rate			0.02%	0.02%
Expected warrant life			3 months 25 days	25 days	4 years 1 month 6 days
Warrant [Member] \| Maximum [Member]
Fair Value Assumptions [Abstract]
Volatility				50.00%	88.10%
Risk-free interest rate			1.30%	1.63%
Expected warrant life			4 years 8 months 23 days	4 years 5 months 23 days	4 years 3 months 29 days
Warrant [Member] \| Level 3 [Member]
Fair Value Measurements Using Significant Unobservable Inputs (Level 3) [Abstract]
Balance as beginning of period			$ 499	$ 499
Initial measurements				2,958
Reclassed from equity				5,399
Increase (decrease) in fair value				(1,814)
Balance as end of period				7,042	$ 499
Warrant [Member] \| Level 3 [Member] \| 10/31/2013 [Member]
Fair Value Measurements Using Significant Unobservable Inputs (Level 3) [Abstract]
Balance as beginning of period			233	233
Initial measurements				0
Reclassed from equity				0
Increase (decrease) in fair value				146
Balance as end of period				379	233
Warrant [Member] \| Level 3 [Member] \| 2/5/2014 [Member]
Fair Value Measurements Using Significant Unobservable Inputs (Level 3) [Abstract]
Balance as beginning of period			266	266
Initial measurements				0
Reclassed from equity				0
Increase (decrease) in fair value				449
Balance as end of period				715	266
Warrant [Member] \| Level 3 [Member] \| 7/24/2014 Series A [Member]
Fair Value Measurements Using Significant Unobservable Inputs (Level 3) [Abstract]
Balance as beginning of period			0	0
Initial measurements				0
Reclassed from equity				3,452
Increase (decrease) in fair value				(1,037)
Balance as end of period				2,415	0
Warrant [Member] \| Level 3 [Member] \| 7/24/2014 Series B [Member]
Fair Value Measurements Using Significant Unobservable Inputs (Level 3) [Abstract]
Balance as beginning of period			0	0
Initial measurements				0
Reclassed from equity				1,947
Increase (decrease) in fair value				(221)
Balance as end of period				1,726	0
Warrant [Member] \| Level 3 [Member] \| 6/22/2015 [Member]
Fair Value Measurements Using Significant Unobservable Inputs (Level 3) [Abstract]
Balance as beginning of period			$ 0	0
Initial measurements				2,958
Reclassed from equity				0
Increase (decrease) in fair value				(1,151)
Balance as end of period				$ 1,807	$ 0

Stockholders' Equity (Details) - USD ($) $ / shares in Units, $ in Thousands				12 Months Ended
	Jul. 24, 2014	Feb. 05, 2014	Oct. 29, 2013	Dec. 31, 2015	Dec. 31, 2014	Dec. 30, 2015	Jun. 22, 2015	Jul. 21, 2014
Class of Stock [Line Items]
Preferred stock, shares authorized (in shares)				10,000,000	10,000,000
Preferred stock, par value (in dollars per share)				$ 0.10	$ 0.10
Preferred stock, shares issued (in shares)				6,505	11,787
Preferred stock, shares outstanding (in shares)				6,505	11,787
Liquidated damages paid to purchasers					$ 3,420
Total preferred stock value				$ 1	$ 1
Common stock, shares authorized (in shares)				150,000,000	150,000,000
Common stock, par value (in dollars per share)				$ 0.001	$ 0.001
Common stock, shares issued (in shares)			422,819	10,283,393	6,037,232
Common stock, shares outstanding (in shares)				10,283,393	6,037,232
Proceeds from issuance of common stock			$ 6,000,000	$ 0	$ 11,458
Class of Warrant or Right [Line Items]
Total Warrants (in shares)				16,729,362
Exercise price (in dollars per share)				$ 0.75		$ 1.13	$ 0.75
Series A Warrants [Member]
Class of Stock [Line Items]
Common stock, par value (in dollars per share)								$ 0.001
Class of Warrant or Right [Line Items]
Exercise price (in dollars per share)	$ 2.45		$ 8.50	$ 0.75				$ 2.45
Warrants issued and outstanding to purchase common stock (in shares)			685,715	6,198,832				6,198,832
Series B warrants [Member]
Class of Warrant or Right [Line Items]
Exercise price (in dollars per share)	$ 2.45			$ 0.75
Warrants issued and outstanding to purchase common stock (in shares)			434,325
Common Stock Warrant One [Member]
Class of Warrant or Right [Line Items]
Issue Date				Apr. 26, 2013
Expiration Date				Apr. 26, 2018
Total Warrants (in shares)				69,321
Exercise price (in dollars per share)				$ 11.18
Common Stock Warrant Two [Member]
Class of Warrant or Right [Line Items]
Issue Date				Oct. 31, 2013
Expiration Date				Apr. 30, 2019
Total Warrants (in shares)				685,715
Exercise price (in dollars per share)				$ 0.75
Common Stock Warrant Three [Member]
Class of Warrant or Right [Line Items]
Issue Date				Feb. 05, 2014
Expiration Date				Feb. 05, 2019
Total Warrants (in shares)				1,329,731
Exercise price (in dollars per share)				$ 0.75
Common Stock Warrant Four [Member]
Class of Warrant or Right [Line Items]
Issue Date				Jul. 24, 2014
Expiration Date				Jul. 24, 2019
Total Warrants (in shares)				6,198,832
Common Stock Warrant Four [Member] \| Minimum [Member]
Class of Warrant or Right [Line Items]
Exercise price (in dollars per share)				$ 0.75
Common Stock Warrant Four [Member] \| Maximum [Member]
Class of Warrant or Right [Line Items]
Exercise price (in dollars per share)				$ 2.45
Common Stock Warrant Five [Member]
Class of Warrant or Right [Line Items]
Issue Date				Jul. 24, 2014
Expiration Date				Jan. 24, 2016
Total Warrants (in shares)				4,795,321
Exercise price (in dollars per share)				$ 0.75
Common Stock Warrant Six [Member]
Class of Warrant or Right [Line Items]
Issue Date				Jun. 22, 2015
Expiration Date				Jun. 22, 2020
Total Warrants (in shares)				3,000,000
Exercise price (in dollars per share)				$ 0.75
Common Stock Warrant Seven [Member]
Class of Warrant or Right [Line Items]
Issue Date				Dec. 30, 2015
Expiration Date				Dec. 30, 2020
Total Warrants (in shares)				650,442
Exercise price (in dollars per share)				$ 1.13
Series B Preferred Stock [Member]
Class of Stock [Line Items]
Preferred stock, shares issued (in shares)				6,505	11,787
Preferred stock, shares outstanding (in shares)				6,505	11,787
Number of preferred stock converted (in shares)	12,300			5,282.5
Conversion of convertible preferred stock, stated value (in dollars per share)	$ 1,000
Initial conversion price (in dollars per share)	$ 2.565
Total preferred stock value	$ 2,487
Intrinsic value of beneficial conversion feature	$ 1,887
Class of Warrant or Right [Line Items]
Exercise price (in dollars per share)	$ 2.45
Warrants issued and outstanding to purchase common stock (in shares)	4,795,321
Series A Preferred Stock [Member]
Class of Stock [Line Items]
Preferred stock, par value (in dollars per share)		$ 0.10
Preferred stock, shares issued (in shares)		12,300
Number of preferred stock converted (in shares)	12,300
Conversion of convertible preferred stock, stated value (in dollars per share)		$ 1,000
Common Stock [Member]
Class of Stock [Line Items]
Number of shares issued upon conversion (in shares)	4,795,321			2,059,455
Common Stock Equivalents of Convertible Preferred Stock [Member]
Class of Stock [Line Items]
Preferred stock, par value (in dollars per share)		$ 0.10
Preferred stock, shares issued (in shares)		12,300
Number of shares issued upon conversion (in shares)		1,464,287
Initial conversion price (in dollars per share)		$ 8.40
Proceeds from issuance of warrants		$ 11,458
Warrant term		5 years
Class of Warrant or Right [Line Items]
Exercise price (in dollars per share)		$ 7.40
Warrants issued and outstanding to purchase common stock (in shares)		1,329,731

Stock-based compensation (Details) - $ / shares	12 Months Ended
Stock-based compensation (Details) - $ / shares	Dec. 31, 2015	Dec. 31, 2014	Sep. 30, 2015	Apr. 25, 2013
Stock Options [Member]
Number of Stock Options [Roll Forward]
Outstanding at beginning period (in shares)	1,308,835	306,616
Granted (in shares)	1,487,500	1,205,162
Exercised (in shares)	0	0
Expired/cancelled (in shares)	(111,983)	(202,943)
Outstanding at end of period (in shares)	2,684,352	1,308,835
Exercisable at end of period (in shares)	1,729,177
Options expected to vest at end of period (in shares)	952,850
Weighted Average Exercise Price [Abstract]
Outstanding at beginning of period (in dollars per share)	$ 2.76	$ 16.20
Granted (in dollars per share)	1.15	1.70
Exercised (in dollars per share)	0	0
Expired/cancelled (in dollars per share)	10.70	16.74
Outstanding at end of period (in dollars per share)	1.54	$ 2.76
Exercisable at end of period (in dollars per share)	1.66
Options expected to vest at end of period (in dollars per share)	$ 1.26
Stock Incentive Plan 2013 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of shares authorized for issuance (in shares)	13,250,000		13,250,000	3,500,000
Number of shares available for issuance (in shares)	10,565,648

Stock-based compensation, Stock Options Plan by Exercise Price Range (Details)	12 Months Ended
	Dec. 31, 2015 $ / shares shares
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Outstanding number of shares (in shares) \| shares	2,684,352
Weighted average remaining contractual life	9 years 4 months 17 days
Weighted average exercise price (in dollars per share)	$ 1.54
Exercisable number of shares (in shares) \| shares	1,729,177
Exercisable weighted average exercise price (in dollars per share)	$ 1.66
$0 - $1.25 [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Lower range limit (in dollars per share)	0
Upper range limit (in dollars per share)	$ 1.25
Outstanding number of shares (in shares) \| shares	1,487,500
Weighted average remaining contractual life	9 years 9 months 18 days
Weighted average exercise price (in dollars per share)	$ 1.15
Exercisable number of shares (in shares) \| shares	1,037,500
Exercisable weighted average exercise price (in dollars per share)	$ 1.14
$1.26 - $5.00 [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Lower range limit (in dollars per share)	1.26
Upper range limit (in dollars per share)	$ 5.00
Outstanding number of shares (in shares) \| shares	1,125,000
Weighted average remaining contractual life	8 years 11 months 12 days
Weighted average exercise price (in dollars per share)	$ 1.40
Exercisable number of shares (in shares) \| shares	625,000
Exercisable weighted average exercise price (in dollars per share)	$ 1.47
$5.01 - $10.00 [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Lower range limit (in dollars per share)	5.01
Upper range limit (in dollars per share)	$ 10.00
Outstanding number of shares (in shares) \| shares	53,402
Weighted average remaining contractual life	7 years 11 months 1 day
Weighted average exercise price (in dollars per share)	$ 6.75
Exercisable number of shares (in shares) \| shares	50,352
Exercisable weighted average exercise price (in dollars per share)	$ 6.74
$10.01 - $63.00 [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Lower range limit (in dollars per share)	10.01
Upper range limit (in dollars per share)	$ 63.00
Outstanding number of shares (in shares) \| shares	18,450
Weighted average remaining contractual life	6 years 7 months 13 days
Weighted average exercise price (in dollars per share)	$ 25.95
Exercisable number of shares (in shares) \| shares	16,325
Exercisable weighted average exercise price (in dollars per share)	$ 26.54

Stock-based compensation, Fair Value Assumptions (Details) - USD ($) $ / shares in Units, $ in Thousands				12 Months Ended
	Dec. 15, 2015	Dec. 01, 2015	Sep. 30, 2015	Dec. 31, 2015	Dec. 31, 2014	Dec. 30, 2015	Jun. 22, 2015
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions and Methodology [Abstract]
Risk-free interest rate - Minimum				1.80%	2.14%
Risk-free interest rate - Maximum				1.90%	2.45%
Volatility - Minimum				50.00%	73.87%
Volatility - Maximum				85.68%	75.51%
Expected dividend yield				0.00%	0.00%
Expected life				6 years 6 months	6 years 6 months
Estimated forfeiture rate				0.00%	0.00%
Share price (in dollars per share)				$ 1.11		$ 1.11	$ 1.38
Stock-based compensation expense				$ 1,753	$ 413
Non-employee stock-based compensation					$ 20
Unrecognized compensation expense				$ 635
Weighted average period of recognition				1 year 1 month 6 days
Expected volatility rate if historical method used				85.19%
Fair value of warrants if historical method used				$ 384
Restricted Stock [Member] \| Chief Executive Officer [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions and Methodology [Abstract]
Shares issued (in shares)	100,000
Purchase price (in dollars per share)	$ 0.01
Aggregate fair value of shares issued	$ 109
Stock Options [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions and Methodology [Abstract]
Share price (in dollars per share)				$ 1.11
Stock Options [Member] \| Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions and Methodology [Abstract]
Expiry period of option				10 years
Stock Options [Member] \| Non-Employee Board Directors [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions and Methodology [Abstract]
Term of vesting		1 year
Expiry period of option		10 years
Shares issued (in shares)		450,000
Purchase price (in dollars per share)		$ 1.18
Aggregate fair value of shares issued		$ 253
Stock Options [Member] \| New Board Director [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions and Methodology [Abstract]
Expiry period of option			10 years
Shares issued (in shares)			37,500
Purchase price (in dollars per share)			$ 1.14
Aggregate fair value of shares issued			$ 31
Stock Options [Member] \| Two Board Directors [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions and Methodology [Abstract]
Expiry period of option			10 years
Shares issued (in shares)			1,000,000
Purchase price (in dollars per share)			$ 1.14
Aggregate fair value of shares issued			$ 826

Income Taxes (Details) - USD ($) $ in Thousands	12 Months Ended
Income Taxes (Details) - USD ($) $ in Thousands	Dec. 31, 2015	Dec. 31, 2014
Income Taxes [Abstract]
Effective income tax rate	34.00%
Difference between income tax benefit and U.S. federal income tax rate to pretax loss from continuing operations [Abstract]
Computed expected tax benefit	$ (8,472)	$ (4,270)
State tax benefit, net of federal effect	(1,365)	(217)
Net increase in valuation allowance	9,956	4,487
Provision for income taxes	119	0
Deferred tax assets/(liabilities) [Abstract]
Net operating loss carryforward	64,075	57,367
Capitalized research and developmental costs	10,543	12,925
Inventory	47	689
Reserves & accrued expenses	3,295	135
Warrant liability	0	(3,123)
Convertible debt discount	(11,182)	0
Property & equipment	(355)	(785)
Non-cash compensation	1,054	3,840
Goodwill	(119)	0
Total deferred tax assets	67,358	71,048
Less: valuation allowance	(67,477)	(71,048)
Net deferred tax assets/(liabilities)	(119)	0
Valuation allowance - Deferred tax asset change in amount	(3,571)	4,487
Federal operating loss carryforwards, net	$ 161,693	$ 144,759
Earliest open tax year subject to examination	2010

Business Segments and Geographic Data (Details) $ in Thousands	12 Months Ended
	Dec. 31, 2015 USD ($) Segment	Dec. 31, 2014 USD ($)
Segment Reporting Information [Line Items]
Number of operating segments \| Segment	3
Number of dermatology procedures segments \| Segment	2
Results of Operations from Business Segments [Abstract]
Revenues	$ 18,495	$ 915
Cost of revenues	13,719	4,935
Gross profit	$ 4,776	$ (4,020)
Gross profit %	25.80%	(439.30%)
Allocated operating expenses [Abstract]
Engineering and product development	$ 2,029	$ 1,641
Selling and marketing expenses	9,194	3,140
Unallocated operating expenses	10,028	7,821
Total operating expenses	21,251	12,602
Income (loss) from operations	(16,475)	(16,622)
Interest expense, net	(10,200)	(2,372)
Change in fair value of warrant liability	1,814	8,103
Gain on sale of assets	0	16
Other income (expense), net	33	150
Registration rights liquidated damages	0	(3,420)
Net loss	(24,828)	(14,145)
Assets	$ 51,372	$ 20,070
Percentage of long lived assets located in domestic markets	100.00%	100.00%
Operating Segments [Member] \| Dermatology Recurring Procedures [Member]
Results of Operations from Business Segments [Abstract]
Revenues	$ 14,616	$ 0
Cost of revenues	4,680	0
Gross profit	$ 9,936	$ 0
Gross profit %	68.00%	0.00%
Allocated operating expenses [Abstract]
Engineering and product development	$ 676	$ 0
Selling and marketing expenses	7,128	0
Unallocated operating expenses	0	0
Total operating expenses	7,804	0
Income (loss) from operations	2,132	0
Interest expense, net	0	0
Change in fair value of warrant liability	0	0
Gain on sale of assets		0
Other income (expense), net	0	0
Registration rights liquidated damages		0
Net loss	2,132	0
Assets	40,420	0
Operating Segments [Member] \| Dermatology Procedures Equipment [Member]
Results of Operations from Business Segments [Abstract]
Revenues	3,591	0
Cost of revenues	1,989	0
Gross profit	$ 1,602	$ 0
Gross profit %	44.60%	0.00%
Allocated operating expenses [Abstract]
Engineering and product development	$ 104	$ 0
Selling and marketing expenses	193	0
Unallocated operating expenses	0	0
Total operating expenses	297	0
Income (loss) from operations	1,305	0
Interest expense, net	0	0
Change in fair value of warrant liability	0	0
Gain on sale of assets		0
Other income (expense), net	0	0
Registration rights liquidated damages		0
Net loss	1,305	0
Assets	5,364	0
Operating Segments [Member] \| Dermatology Imaging [Member]
Results of Operations from Business Segments [Abstract]
Revenues	288	915
Cost of revenues	7,050	4,935
Gross profit	$ (6,762)	$ (4,020)
Gross profit %	(2347.80%)	(439.30%)
Allocated operating expenses [Abstract]
Engineering and product development	$ 1,249	$ 1,641
Selling and marketing expenses	1,873	3,140
Unallocated operating expenses	0	0
Total operating expenses	3,122	4,781
Income (loss) from operations	(9,884)	(8,801)
Interest expense, net	0	0
Change in fair value of warrant liability	0	0
Gain on sale of assets		0
Other income (expense), net	0	0
Registration rights liquidated damages		0
Net loss	(9,884)	(8,801)
Assets	661	19,181
Reportable Geographical Components [Member] \| Domestic [Member]
Results of Operations from Business Segments [Abstract]
Revenues	14,724	340
Reportable Geographical Components [Member] \| Foreign [Member]
Results of Operations from Business Segments [Abstract]
Revenues	3,771	575
Other Unallocated Assets [Member]
Allocated operating expenses [Abstract]
Assets	$ 4,927	$ 889

Related Parties (Details) $ / shares in Units, $ in Thousands			6 Months Ended	12 Months Ended
	Nov. 04, 2015 USD ($)	Jun. 22, 2015 USD ($) shares $ / shares	Dec. 31, 2015 USD ($) $ / shares shares	Dec. 31, 2015 USD ($) shares $ / shares	Dec. 30, 2015 $ / shares shares
Related Party Transaction [Line Items]
Number of shares underlying warrants (in shares) \| shares		3,000,000	3,000,000	3,000,000	650,442
Exercise price of warrants (in dollars per share) \| $ / shares		$ 0.75	$ 0.75	$ 0.75	$ 1.13
Percentage of liquidated damages payable			2.00%
Percentage of aggregate liquidated damages payable			12.00%
Interest rate payable on liquidated damages			12.00%
Percentage of issued and outstanding common stock payable upon conversion			9.99%
Senior Secured 2.25% Convertible Debentures [Member]
Related Party Transaction [Line Items]
Aggregate principal amount of debt		$ 32,500	$ 32,500	$ 32,500
Interest rate			2.25%	2.25%
Number of shares debt convertible (in shares) \| shares		43,333,334		43,333,334
Initial conversion price (in dollars per share) \| $ / shares		$ 0.75	$ 0.75	$ 0.75
Debt instrument, maturity period		5 years		5 years
Senior Secured Notes Payable [Member]
Related Party Transaction [Line Items]
Aggregate principal amount of debt		$ 10,000
Number of days for stockholders approval considered for maturity date		30 days		30 days
Interest rate			9.00%	9.00%
Two Board Directors [Member]
Related Party Transaction [Line Items]
Up-front fee paid to directors	$ 40,000
Retainer amount per month	$ 10,000

Significant Customer Concentration (Details) - Customer Concentration Risk [Member] $ in Thousands	12 Months Ended
	Dec. 31, 2015 USD ($)
Product Information [Line Items]
Revenues	$ 3,085
Accounts receivable	$ 533
Revenue [Member]
Product Information [Line Items]
Concentration risk percentage	16.70%
Accounts Receivable [Member]
Product Information [Line Items]
Concentration risk percentage	13.10%

Subsequent Events (Details) $ / shares in Units, $ in Thousands	Mar. 11, 2016 USD ($) shares	Mar. 03, 2016 USD ($) shares	Feb. 24, 2016 USD ($) shares	Jan. 29, 2016 USD ($) $ / shares shares	Jan. 22, 2016 Tranche $ / shares shares	Dec. 31, 2015 $ / shares	Dec. 30, 2015 $ / shares	Jun. 22, 2015 $ / shares
Subsequent Events [Line Items]
Exercise price of warrants (in dollars per share) \| $ / shares						$ 0.75	$ 1.13	$ 0.75
Subsequent Event [Member]
Subsequent Events [Line Items]
Number of tranches \| Tranche					2
Term of extension					6 months
Debentures converted in shares of common stock, value \| $	$ 113	$ 38	$ 15
Debentures converted in shares of common stock (in shares) \| shares	150,000	50,000	20,000
Subsequent Event [Member] \| Credit Facility [Member]
Subsequent Events [Line Items]
Maximum borrowing capacity under the agreement \| $				$ 12,000
Subsequent Event [Member] \| Credit Facility [Member] \| Second Tranche [Member]
Subsequent Events [Line Items]
Warrants issued to purchase common stock (in shares) \| shares				99,057
Exercise price of warrants (in dollars per share) \| $ / shares				$ 1.06
Proceeds from credit facility \| $				$ 1,500
Warrant term				5 years
Subsequent Event [Member] \| Common Stock [Member]
Subsequent Events [Line Items]
Warrants issued to purchase common stock (in shares) \| shares					4,795,321
Exercise price of warrants (in dollars per share) \| $ / shares					$ 0.75

CONSOLIDATED STATEMENT OF CHANGES IN STOCKHOLDERS' EQUITY (Parenthetical) $ in Thousands	12 Months Ended
	Dec. 31, 2014 USD ($)
CONSOLIDATED STATEMENT OF CHANGES IN EQUITY [Abstract]
Issuance cost of common stock and warrants	$ 992

CONSOLIDATED STATEMENTS OF CASH FLOWS (Parenthetical) $ in Thousands	12 Months Ended
	Dec. 31, 2015 USD ($)
Cash Flows From Investing Activities:
Cash acquired	$ 0